9-11-2012

Cytochrome P450S and Uses Thereof

Joe Chappell  
*University of Kentucky, chappell@uky.edu*

Lyle F. Ralston

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Follow this and additional works at: [https://uknowledge.uky.edu/pss_patents](https://uknowledge.uky.edu/pss_patents)  
Part of the [Plant Sciences Commons](https://uknowledge.uky.edu/pss_patents)

**Recommended Citation**  
[https://uknowledge.uky.edu/pss_patents/9](https://uknowledge.uky.edu/pss_patents/9)

This Patent is brought to you for free and open access by the Plant and Soil Sciences at UKnowledge. It has been accepted for inclusion in Plant and Soil Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
UNITED STATES PATENT
Chappell et al.

COPYRIGHT P450S AND USES THEREOF

Inventors: Joseph Chappell, Lexington, KY (US); Lyle F. Rabston, Kirkwood, MO (US)

Assignee: University of Kentucky Research Foundation, Lexington, KY (US)

Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 32 days.

This patent is subject to a terminal disclaimer.

Applied No.: 12/182,000
Filed: Jul. 29, 2008

Prior Publication Data

Related U.S. Application Data
Continuation of application No. 10/979,559, filed on Mar. 8, 2002, nowPat. No. 7,405,057.

Provisional application No. 60/274,421, filed on Mar. 9, 2001, provisional application No. 60/275,597, filed on Mar. 13, 2001.

Int. Cl.
C12N 1/00 (2006.01)
C12N 1/06 (2006.01)
C12N 5/00 (2006.01)
C12N 5/07 (2010.01)

U.S. Cl. .... 435/69.1; 435/419; 435/348; 435/252.1; 435/252.2

Field of Classification Search
See application file for complete search history.

References Cited

U.S. PATENT DOCUMENTS
5,589,619 A 12/1996 Chappell et al. .......... 800/205
5,672,487 A 9/1997 Schwen et al................. 800/205
5,741,674 A 4/1998 Schwen et al................. 800/205
5,824,774 A 10/1998 Chappell et al. .......... 800/205
5,938,843 A 11/1999 Chappell et al. .......... 800/301
5,939,114 A 11/1999 Croteau et al. ........... 435/232
6,100,451 A 8/2000 Chappell et al. .......... 800/298
6,117,649 A 9/2000 Bellame et al.............. 800/298
6,194,185 B1 2/2001 Croteau et al.............. 800/298
6,331,660 B1 12/2001 Chomet et al.............. 800/298
6,368,837 B1 12/2001 Gateley et al............. 800/298
6,468,772 B1 10/2002 Chappell et al. .......... 435/183
6,553,203 B1 3/2003 Mills et al. .............. 435/155
6,689,593 B2 2/2004 Mills et al. .............. 435/155
7,482,785 B2 10/2008 Chappell et al. .......... 435/69.1

FOREIGN PATENT DOCUMENTS
WO 96/36697 11/1996
WO 97/38571 10/1997
WO 97/38703 10/1997
WO 97/37664 10/1997
WO 00/17327 3/2000
WO 02/07758 9/2002
WO 2010/01696 2/2010

OTHER PUBLICATIONS

(Continued)

Primary Examiner — Medina A Ibrahim
Attorney, Agent, or Firm — McKenna Long & Aldridge LLP; Stephanie Seidman

ABSTRACT

The invention features isolated cytochrome P450 polypeptides and nucleic acid molecules, as well as expression vectors and transgenic plants containing these molecules. In addition, the invention features uses of such molecules in methods of increasing the level of resistance against a disease caused by a plant pathogen in a transgenic plant, in methods for producing altered compounds, for example, hydroxylated compounds, and in methods of producing isoprenoid compounds.

20 Claims, 11 Drawing Sheets
OTHER PUBLICATIONS


GenBank Accession No. X96784, 1996.

GenBank Accession No. Y09447.


Allyls, “Protein engineering and chemiosynthesis to produce novel sesquiterpenoids,” Presentation at BIO World Congress on Industrial Biotechnology & Bioprocessing, Washington, D.C., held on June 28, 2010, 19 pages.


* cited by examiner
FIG. 1

farnesyl diphosphate → EAS → 1-deoxycapsidiol (3-hydroxy-5-epi-aristolochene) → 5-epi-aristolochene → 3-deoxycapsidiol (1-hydroxy-5-epi-aristolochene) → capsidiol

+ NADPH + O₂
FIG. 2

![Graph showing enzyme activity over time](image-url)

- **Y-axis:** Enzyme activity (% of maximum)
- **X-axis:** Time after elicitation (h)

- Three lines demonstrate enzyme activity over time, peaking at different times.
- The first line peaks at approximately 21 hours after elicitation.
- The second line peaks at 18 hours.
- The third line remains relatively flat, indicating minimal activity.

The graph visualizes the dynamic response of enzyme activity following elicitation.
**FIG. 3A**

Enzyme activity (% of maximum) vs. Inhibitor concentration (µM)

**FIG. 3B**

Enzyme activity (% of maximum) vs. Inhibitor concentration (µM)
FIG. 4A

KETLRLH-for  5'-AARGARACIYTIMGIYTIACA-3'
KETLRLY-for  5'-AARGARACIYTIMGIYTIITA-3'
KETLRLR-for  5'-AARGARACIYTIMGIYTIMG-3'
FXPERF-for   5'-TTYIICCGIGARMGITTY-3'
FXPERF-rev   5'-RAAIICKYTCIGGIIIRA-3'
GRRXCP(A/G)-for  5'-GGIMGIGIIIITGYCCIGS-3'
PFGXGRR-rev   5'-CICKICCIICCRAAIGG-3'
T7            5'-GTAATACGACTCACTATAGGG-3'
T3            5'-CAATTAACCCTCACTAAAGGG-3'

FIG. 4C
FIG. 5

<table>
<thead>
<tr>
<th></th>
<th>control</th>
<th>0</th>
<th>24</th>
<th>0.5</th>
<th>1.5</th>
<th>3</th>
<th>6</th>
<th>9</th>
<th>12</th>
<th>18</th>
<th>24</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP71D</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP73A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP82E</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP92A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EAS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loading control</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
FIG. 7A
71D A+
71D A-

FIG. 7B
empty A+
empty A-

FIG. 7C
71D D+
71D D-

FIG. 7D
empty D+
empty D-
CYTOCHROME P450S AND USES THEREOF

RELATED APPLICATIONS

This application claims the benefit of the priority date of U.S. patent application Ser. No. 10/097,559 filed on Mar. 8, 2002 (now issued U.S. Pat. No. 7,405,037), which claims the benefit of U.S. Provisional Application Nos. 60/274,421 and 60/275,597, filed on Mar. 9, 2001 and Mar. 13, 2001, respectively, all of which are hereby incorporated by reference.

FIELD OF THE INVENTION

This invention relates to cytochrome P450s and uses thereof.

BACKGROUND OF THE INVENTION

Cytochrome P450s encompass a superfamily of oxidases responsible for the oxidation of numerous endobiotics and thousands of xenobiotics. In addition, in plants, cytochrome P450s play important roles in wounded healing, pest resistance, signaling, and anti-microbial and anti-fungal activity.

Capsidol is a bicyclic, dihydroxylated sesquiterpene produced by many Solanaceous species in response to a variety of environmental stimuli, including exposure to UV (Baek et al., Plant Cell. Physiol. 38:899-904, 1998) and infection by microorganisms (Molot et al., Physiol. Plant Pathol. 39:379-389, 1981; Stolle et al., Phytopathology 78:1193-1197, 1988; Keller et al., Planta. 205:467-476, 1998). It is the primary antibiotic or phytoalexin produced in tobacco in response to fungal elicitation, and it is derived from the isopenrenoid pathway via its hydrocarbon precursor, 5-epi-aristolochene (FIG. 1). Several of the biosynthetic enzymes leading up to 5-epi-aristolochene formation have been studied (Vogeli and Chappell, Plant Physiol. 88:1291-1296, 1988; Back and Chappell, Proc. Natl. Acad. Sci. U.S.A. 93:6841-6845, 1996; Mathis et al., Biochemistry 36:8340-8348, 1997; Starski et al., Science 277:1815-1820, 1997). BAS commits to sesquiterpene metabolism by catalyzing the cyclization of farnesyl diphosphate (FPP) to 5-epi-aristolochene. However, until the present invention, the biochemical evidence from previous studies in tobacco (Whitehead et al., Phytochemistry 28:775-779, 1989) and green pepper (Hoshino et al., Phytochemistry 38:609-613, 1995) have suggested that the oxidation of 5-epi-aristolochene to capsidol occurs in a two-step process with one of the hydroxylation steps being constitutive and the other being mediated by an elicitor-inducible cytochrome P450 (FIG. 1). Because 1-deoxycapsidol had been isolated from natural sources (Watson et al., Biochem. Soc. Trans. 11:589, 1983), Whitehead et al. (Phytochemistry 28:775-779, 1989), surmised that perhaps the biosynthesis of this intermediate was due to pathogen induction of a corresponding hydroxylase. They therefore prepared synthetic 1-deoxycapsidol and reported a modest conversion of this compound to capsidol when fed to control or unelicited tobacco cell cultures. This was further supported by their observation that radiolabeled 5-epi-aristolochene was only converted to capsidol when fed to elicitor-induced cell cultures but not control cultures. Whitehead et al. (Phytochemistry 28:775-779, 1989) therefore concluded that the 3-hydroxylase, responsible for hydroxylation of 5-epi-aristolochene at C3 to generate 1-deoxycapsidol, was pathogen/elicitor inducible, while the 1-hydroxylase, responsible for hydroxylating 1-deoxycapsidol at the C1 to generate capsidol, was constitutive. Hoshino et al. (Phytochemistry 38:609-613, 1995), added to the observations of Whitehead et al. (Phytochemistry 28:775-779, 1989) by directly measuring 3-hydroxylase-activity in microbial preparations of arachidonic acid-elicited Capsicum annuum fruits and seedlings. These assays consisted of incubating 5-epi-aristolochene with microbial preparations and subsequently determining the amount of 1-deoxycapsidol generated by a combination of thin-layer chromatography (TLC) separations and gas chromatography (GC). Their evidence demonstrated that the conversion of 5-epi-aristolochene to 1-deoxycapsidol was dependent on both NADPH and O2, and that 1-deoxycapsidol accumulation in vitro was arrested by the P450 antioxidants carbon monoxide (Omura and Sato, J. Biol. Chem. 239:2370-2378, 1964), anacymidal (Coolbaugh et al., Plant Physiol. 62:571-576, 1978), and ketocoumazole (Radenacher, Annu. Rev. Plant Physiol. Plant Mol. Biol. 51:583-604, 2000). Recent results suggest that the hydroxylation of 5-epi-aristolochene is an important regulated step in capsidol biosynthesis. In studies to evaluate the effectiveness of methyljasmonate as an inducer of capsidol biosynthesis in tobacco cell cultures, Mandujano-Chávez et al. (Arch. Biochem. Biophys. 381:285-294, 2000), reported that the modest accumulation of this phytoalexin was accompanied by a strong induction of EAS. This result implied that steps before or after the sesquiterpene cyclase reaction were limiting. Using an in vivo assay measuring the conversion rate of radiolabeled 5-epi-aristolochene to capsidol, a very limited induction of the hydroxylase activities was observed in cells treated with methyl jasmonate relative to that in fungal elicitor-treated cells. This result pointed to the hydroxylase reactions as a potentially limiting step in capsidol biosynthesis.

SUMMARY OF THE INVENTION

In one aspect, the invention features several isolated cytochrome P450 polypeptides (such as CYP71D20, CYP71D21, CYP73A27, CYP73A28, and CYP92A5, and P450s having substantial identity to these polypeptides), as well as isolated nucleic acid molecules that encode these P450s.

In related aspects, the invention features a vector (such as an expression vector) including an isolated nucleic acid molecule of the invention and a cell (for example, a prokaryotic cell, such as Agrobacterium or E. coli, or a eukaryotic cell, such as a mammalian, insect, yeast, or plant cell) including the isolated nucleic acid molecule or vector.

In yet another aspect, the invention features a transgenic plant or transgenic plant component including a nucleic acid molecule of the invention, wherein the nucleic acid molecule is expressed in the transgenic plant or the transgenic plant component. Preferably, the transgenic plant or transgenic plant component is an angiosperm (for example, a monocot or dicot). In preferred embodiments, the transgenic plant or transgenic plant component is a solanaceous, maize, rice, or cruciferous plant or a component thereof. The invention further includes a seed produced by the transgenic plant or transgenic plant component, or progeny thereof.

In another aspect, the invention features a method of providing an increased level of resistance against a disease caused by a plant pathogen in a transgenic plant. The method involves: (a) producing a transgenic plant cell including the nucleic acid molecule of the invention integrated into the genome of the transgenic plant cell and positioned for expression in the plant cell; and (b) growing a transgenic plant from the plant cell wherein the nucleic acid molecule is expressed in the transgenic plant and the transgenic plant is thereby
provided with an increased level of resistance against a disease caused by a plant pathogen.

In another aspect, the invention features a method for producing an altered compound, the method including the steps of contacting the compound with one or more of the isolated polypeptides disclosed herein under conditions allowing for the hydrolysis, oxidation, demethylation, or methylation of the compound and recovering the altered compound.

In still another aspect, the invention features a hydroxylytating agent including any of the isolated polypeptides disclosed herein.

In yet another embodiment, the invention features an isolated nucleic acid molecule that specifically hybridizes under highly stringent conditions to the complement of any one of the sequences described in SEQ ID NO:2 (CYP71D20), SEQ ID NO:4 (CYP71D21), SEQ ID NO:6 (CYP73A27), SEQ ID NO:8 (CYP73A28), or SEQ ID NO: 12 (CYP92A5), wherein such a nucleic acid molecule encodes a cytochrome P450 polypeptide.

In another aspect, the invention features a host cell expressing a recombinant isoproenoid synthase and a recombinant cytochrome P450. In preferred embodiments, the host cell further expresses, independently or in combination, a recombinant acetyltransferase, methyltransferase, or fatty acyltransferase. In other preferred embodiments, the host expresses an endogenous or recombinant cytochrome reductase. Preferably, the host cell is a yeast cell, a bacterial cell, an insect cell, or a plant cell.

In a related aspect, the invention features a method for producing an isoproenoid compound, the method including the steps of: (a) culturing a cell that expresses a recombinant isoproenoid synthase and a recombinant cytochrome P450 under conditions wherein the isoproenoid synthase and the cytochrome P450 are expressed and catalyze the formation of an isoproenoid compound not normally produced by the cell; and (b) recovering the isoproenoid compound. In preferred embodiments, the host cell further expresses a recombinant acetyltransferase, a recombinant methyltransferase, or a recombinant fatty acyltransferase. In other preferred embodiments, the host cell expresses an endogenous or recombinant cytochrome reductase. Preferably, the host cell is a yeast cell, a bacterial cell, an insect cell, or a plant cell.

In yet another aspect, the invention features an isoproenoid compound produced according to the above-mentioned methods.

By “P450 polypeptide,” “cytochrome P450,” or “P450” is meant a polypeptide that contains a heme-binding domain and shows a CO absorption spectra peak at 450 nm according to standard methods, for example, those described herein. Such P450s may also include, without limitation, hydroxylase activity, dual hydroxylase activity, demethylation activity, or oxidase activity. Such enzymatic activities are determined using methods well known in the art.

By “polypeptide” is meant any chain of amino acids, regardless of length or post-translational modification (for example, glycosylation or phosphorylation).

By “substantially identical” is meant a polypeptide or nucleic acid exhibiting at least 80% 85%, preferably 90%, more preferably 95%, and most preferably 97%, or even 98% identity to a reference amino acid sequence (for example, the amino acid sequence shown in SEQ ID NO:1, 3, 5, 7, and 11) or nucleic acid sequence (for example, the nucleic acid sequences shown in SEQ ID NO:2, 4, 6, 8, and 12, respectively). For polypeptides, the length of comparison sequences will generally be at least 16 amino acids, preferably at least 20 amino acids, and most preferably at least 25 amino acids, and most preferably 35 amino acids. For nucleic acids, the length of comparison sequences will generally be at least 50 nucleotides, preferably at least 60 nucleotides, more preferably at least 75 nucleotides, and most preferably 110 nucleotides.

Sequence identity is typically measured using sequence analysis software (for example, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, W1 53705, BLAST, or PILEUP/PRETTYBOX programs). Such software matches identical or similar sequences by assigning degrees of homology to various substitutions, deletions, and/or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine alanine, valine isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine threonine; lysine arginine; and phenylalanine, tyrosine.

By an “isolated polypeptide” is meant a P450 polypeptide (for example, a CYP71D20 (SEQ ID NO: 1), CYP71D21 (SEQ ID NO:3), CYP73A27 (SEQ ID NO:5), CYP73A28 (SEQ ID NO:7), or CYP92A5 (SEQ ID NO:11) polypeptide) that has been separated from components that naturally accompany it. Typically, the polypeptide is isolated when it is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, a P450 polypeptide. An isolated P450 polypeptide may be obtained, for example, by extraction from a natural source (for example, a plant cell); by expression of a recombinant nucleic acid encoding a P450 polypeptide; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, for example, column chromatography, polyacrylamide gel electrophoresis, or by HPLC analysis.

By “derived from” or “obtained from” is meant isolated from or having the sequence of a naturally-occurring sequence (e.g., cDNA, genomic DNA, synthetic, or combination thereof).

By “isolated nucleic acid molecule” is meant a nucleic acid molecule, e.g., a DNA molecule, that is free of the nucleic acid sequence(s) which, in the naturally-occurring genome of the organism from which the nucleic acid molecule of the invention is derived, flank the nucleic acid molecule. The term therefore includes, for example, a recombinant DNA that is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or that exists as a separate molecule (for example, a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. The term “isolated nucleic acid molecule” also includes a recombinant DNA which is part of a hybrid gene encoding additional polypeptide sequence.

By “specifically hybridizes” is meant that a nucleic acid sequence is capable of hybridizing to a DNA sequence at least under low stringency conditions, and preferably under high stringency conditions. For example, high stringency conditions may include hybridization at approximately 42°C in about 50% formamide, 0.1 mg/ml sheared salmon sperm DNA, 1% SDS, 2xSSC, 10% Dextran sulfate, a first wash at approximately 65°C in about 2xSSC, 1% SDS, followed by a second wash at approximately 65°C in about 0.1xSSC. Alternatively high stringency conditions may include hybridization at approximately 42°C in about 50% formamide, 0.1 mg/ml sheared salmon sperm DNA, 0.5% SDS, 5xSSPE, 1xDenhardt’s, followed by two washes at room temperature in 2xSSC, 0.1% SDS, and two washes at between 55-60°C in 0.2xSSC, 0.1% SDS. Reducing the stringency of the
hybridization conditions may involve lowering the wash temperature and/or washing at a higher concentration of salt. For example, low stringency conditions may include washing in 2xSSC, 0.1% SDS at 40°C.

By “transformed cell” is meant a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a DNA molecule encoding (as used herein) a P450 polypeptide.

By “positioned for expression” is meant that the DNA molecule is positioned adjacent to a DNA sequence which directs transcription and translation of the sequence (i.e., facilitates the production of, for example, a P450 polypeptide, a recombinant protein, or an RNA molecule).

By “reporter gene” is meant a gene whose expression may be assayed; such genes include, without limitation, beta-glucuronidase (GUS), luciferase, chloramphenicol transacyetylase (CAT), green fluorescent protein (GFP), beta-galactosidase, herbicide resistant genes, and antibiotic resistance genes.

By “expression control region” is meant any minimal sequence sufficient to direct transcription. Included in the invention are promoter elements that are sufficient to render promoter-dependent gene expression controllable for cell-, tissue-, or organ-specific gene expression, or elements that are inducible by external signals or agents (for example, light-, pathogen-, wound-, stress-, or hormone-inducible elements or chemical inducers such as salicylic acid (SA) or 2,2-dichloroisonicotinic acid (INA)); such elements may be located in the 5’ or 3’ regions of the native gene or engineered into a transgene construct.

By “operably linked” is meant that a gene and a regulatory sequence(s) are connected in such a way as to permit gene expression when the appropriate molecules (for example, transcriptional activator proteins) are bound to the regulatory sequence(s).

By “plant cell” is meant any self-propagating cell bounded by a semi-permeable membrane and typically is one containing a plastid. Such a cell also requires a cell wall if further propagation is desired. Plant cell, as used herein includes, without limitation, algae, cyanobacteria, seeds, suspension cultures, embryos, meristematic regions, callus tissue, leaves, roots, shoots, gametophytes, sporophytes, pollen, and microspores.

By “plant component” is meant a part, segment, or organ obtained from an intact plant or plant cell. Exemplary plant components include, without limitation, somatic embryos, leaves, stems, roots, flowers, tendrils, fruits, scions, and rootstocks.

By “transgene” is meant any piece of DNA which is inserted into an eukaryotic cell and typically becomes part of the genome, for example, the nuclear or plastidic genome, of the organism which develops from that cell. Such a transgene may include a gene which is partly or entirely heterologous (i.e., foreign) to the transgenic organism, or may represent a gene homologous to an endogenous gene of the organism.

By “transgenic” is meant any cell which includes a DNA sequence which is inserted into an eukaryotic cell and becomes part of the genome of the organism which develops from that cell. As used herein, the transgenic organisms are generally transgenic plants and the DNA (transgene) is inserted by artifice into the nuclear or plastidic genome. A transgenic plant according to the invention may contain one or more engineered traits.

By “pathogen” is meant an organism whose infection of viable plant tissue elicits a disease response in the plant tissue. Such pathogens include, without limitation, bacteria, mycoplasmas, fungi, insects, nematodes, viruses, and viroids. Plant diseases caused by these pathogens are described in Chapters 11-16 of Agrios, Plant Pathology, 3rd ed., Academic Press, Inc., New York, 1988.

By “increased level of resistance” is meant a greater level of resistance to a disease-causing pathogen in a transgenic plant (or cell or seed thereof) of the invention than the level of resistance relative to a control plant (for example, a non-transgenic plant). In preferred embodiments, the level of resistance in a transgenic plant of the invention is at least 20% (and preferably 30% or 40%) greater than the resistance of a control plant. In other preferred embodiments, the level of resistance to a disease-causing pathogen is 50%, greater, 60% greater, and more preferably even 75% or 90% greater than a control plant; with up to 100% above the level of resistance as compared to a control plant being most preferred. The level of resistance is measured using conventional methods. For example, the level of resistance to a pathogen may be determined by comparing physical features and characteristics (for example, plant height and weight, or by comparing disease symptoms, for example, delayed lesion development, reduced lesion size, leaf wilting and curling, water-soaked spots, and discoleration of cells) of transgenic plants.

By “purified antibody” is meant antibody which is at least 60%, by weight, free from proteins and naturally-occurring organic molecules with which it is naturally associated. Preferably, the preparation is at least 75%, more preferably 90%, and most preferably at least 99%, by weight, antibody, for example, an acquired resistance polypeptide-specific antibody. A purified P450 antibody may be obtained, for example, by affinity chromatography using a recombinantly-produced P450 polypeptide and standard techniques.

By “specifically binds” is meant an antibody which recognizes and binds a P450 protein but which does not substantially recognize and bind other molecules in a sample, for example, a biological sample, which naturally includes a P450 protein such as CYP71D20, CYP71D21, CYP73A27, CYP73A28, or CYP92A5.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments thereof, and from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a schematic diagram of a proposed alternative pathway for the biosynthesis of capsidol in elicitor-treated Nicotiana tabacum cells. 5-epi-aristolochene is synthesized from FPP by the action of a sesquiterpene cyclase, 5-epi-aristolochene synthase (EAS), and is subsequently hydroxylated at C1 and C3 to form capsidol.

FIG. 2 is a graph showing an induction time course for sesquiterpene cyclase enzyme activity and sesquiterpene hydroxylase activity in celluless-treated cell cultures. Sesquiterpene cyclase (5-epi-aristolochene synthase, EAS) enzyme activity was determined in extracts prepared from control (open squares) and elicitor-treated (closed squares) cells collected at the indicated time points. Sesquiterpene hydroxylase activity was determined using an indirect assay for control (open circles) and elicitor-treated (closed circles) cells. Cell cultures were incubated with [3H]-5-epi-aristolochene for 3 hours ending at the indicated time points before quantifying the incorporation of radioactivity into extracellular capsidol, a dihydroxylated form of aristolochene (Mandujano-Chávez et al., Arch. Biochem. Biophys. 381:285-294, 2000).

FIG. 3 is a series of graphs showing the dose dependent inhibition of 5-epi-aristolochene hydroxylase activity by ancyridiol and ketoconazole. Cell cultures were incubated in
the presence of cellulase (0.5 µg/mL) plus the indicated concentrations of ancyelidol (A) or ketoconazole (B) for 12 hours prior to measuring the in vivo 5-epi- aristolochene hydroxylase activity in the cell suspension cultures (squares), or the EAS enzyme activity in extracts prepared from the collected cells (triangles). The in vitro activity of a purified EAS preparation (Back and Chappell, J. Biol. Chem. 270:7375-7381, 1995) was also measured at the indicated inhibitor concentrations as an additional test for non-specific effects of these inhibitors (circles).

FIG. 4A is a schematic diagram of the primary structure of a generalized cytochrome P450 with conserved domains used for the design of PCR primers highlighted (SEQ ID NOS: 26-29).

FIG. 4B is a list of the degenerate P450-specific primers (SEQ ID NOS: 30-36) that were used in various combinations with vector specific primers in the amplification of cytochrome P450 cDNA fragments.

FIG. 4C is a scanned image of an ethidium bromide-stained agarose gel showing the PCR products amplified from a directionally cDNA library prepared with mRNA isolated from elicitor-treated cells using the degenerate primer GRRXCP (A/G)—for (SEQ ID NO: 35) and the T7 vector-specific primer (SEQ ID NO: 37). The T3 vector-specific primer is also shown (SEQ ID NO: 38).

FIG. 5 is a series of Northern blots showing the induction time course for CYP71A, CYP73A, CYP82E, CYP92A, and EAS transcript accumulation in elicitor treated cells. Total RNA was extracted from tobacco suspension cells incubated with the cellulase elicitor for the indicated durations, size fractionated by agarose gel electrophoresis under denaturing conditions, and transferred to a nylon membrane before probing with the respective full-length cDNAs. The uniformity of sample loading was verified by ethidium bromide staining of ribosomal RNA (Loading control).

FIG. 6 is a series of graphs showing carbon monoxide (CO) difference spectra of the microsomal fraction isolated from yeast expressing the CYP92A5 (A) and CYP71D20 (B) cDNAs. Expression of the respective plastidic mRNAs engineered into yeast (WAT11) cells was induced by a galactose treatment, followed by isolation of microsomal preparations. The difference absorption spectra of microsomes incubated in the presence (solid lines) and absence (broken lines) of carbon monoxide was determined.

FIG. 7 is a series of gas chromatograms of the reaction products formed upon incubation of microsomes isolated from WAT11 yeast cells containing the CYP71D20 expression construct (A and C) or vector control DNA (B and D) with sesquiterpene substrates. Microsomes isolated from the indicated yeast lines were incubated with 5-epi-aristolochene (A and B) or 1-deoxyxypsidol (C and D) in the presence (solid lines) or absence (dashed lines) of NADPH. The identities of 5-epi-aristolochene, 1-deoxyxypsidol, and capsidiol were verified by mass spectrometry.

FIGS. 8A-8D provide a sequence comparison of the amino acid sequence of Nicotiana tabacum 5-epi-aristolochene (sesquiterpene) hydroxylase NCYP71D20 (SEQ ID NO: 1) with other plant terpene hydroxylases (SEQ ID NO: 39-43). NCYP71A5v1 (GenBank accession number CA A70575) catalyzes the mono-hydroxylation of neryl and geranyl, linear monoterpenes, while PaCYP71A1 (A35867) catalyzes the epoxidation of these substrates (Hallahan et al., Biochem. Biophys. Acta. 1201:94-100, 1994). MsCYP71D18 (AAD44150) and MpcYP71D13 (AAD44151) catalyze the mono-hydroxylation at C6 and C3 of limonene, a cyclic monoterpenes, respectively (Laupien et al., Arch. Biochem. Biophys. 308:181-192, 1999). AICYP701A3 (AAC39505) encodes for kaurene oxidase, which catalyzes a 3-step reaction including a hydroxylation followed by oxidation of a diterpene (Helliwell et al., Plant Physiol. 119:507-510, 1999). Shown are sequences from Mentha piperita (MpcYP71D13; SEQ ID NO: 39), Mentha spicata (MsCYP71D18; SEQ ID NO: 40), Nepeta racemosa (NcCYP71ASv1; SEQ ID NO: 41), Nicotiana tabacum (NCYP71D20; SEQ ID NO: 41), and Arabidopsis thaliana (CYP701A3; SEQ ID NO: 43). Conserved residues are shaded.

DETAILED DESCRIPTION

Capsidiol is a bicyclic, dihydroxyalted sesquiterpene produced by several Solanaceae species in response to a variety of environmental stimuli. It is the primary antimicrobial compound produced by Nicotiana tabacum in response to fungal elicitation, and it is formed via the isopenoid pathway from 5-epi-aristolochene. Much of the biosynthetic pathway for the formation of this compound has been elucidated, except for the enzyme(s) responsible for the conversion of the allylic sesquiterpene 5-epi-aristolochene to its dihydroxylated form, capsidiol.

Accordingly, an in vivo assay for 5-epi-aristolochene hydroxylase activity was developed and used to demonstrate a dose dependent inhibition of activity by ancyelidol and ketoconazole, two well-characterized inhibitors of cytochrome P450 enzymes. Using degenerate oligonucleotide primers designed to the well-conserved domains found within most P450 enzymes, including the heme binding domain, cDNA fragments representing four distinct P450 families (CYP71, CYP73, CYP82, and CYP92) were amplified from a cDNA library prepared against mRNA from elicitor-treated cells using PCR. The PCR fragments were subsequently used to isolate full-length cDNAs (CYP71D20 (SEQ ID NO: 2) and D21 (SEQ ID NO: 4), CYP73A27 (SEQ ID NO: 6) and A28 (SEQ ID NO: 8), CYP82E1 (SEQ ID NO: 10), and CYP92A5 (SEQ ID NO: 12)), and these in turn were used to demonstrate that the corresponding mRNAs were all included in elicitor-treated cells, albeit with different induction patterns.

There now follows a description of the cloning of several P450s from Nicotiana tabacum. These examples are provided for the purpose of illustrating the invention, and are not to be considered as limiting.

Inhibition of the 5-epi-aristolochene to Capsidiol Conversion by P450 Antagonists

Using an indirect assay, a detailed induction time course of 5EAI activity in elicitor-induced cell cultures was determined relative to that of EAS activity (FIG. 2), the well-characterized sesquiterpene cyclase activity that catalyzes the formation of 5-epi-aristolochene from FPP (FIG. 1). Using assays for EAS and 5EAI, EAS activity is not detectable in control cell cultures, but is induced significantly within 3 hours and reaches its maximal level within 15 to 18 hours of elicitor-treatment. Similar to the EAS enzyme activity, 5EAI activity was negligible in control cell cultures. Nonetheless, after an apparent lag phase of 8 hours, a rapid induction of hydroxylase activity was observed 10 to 15 hours post elicitor addition to the cell cultures, reaching a maximum by 18 hours followed by a rather gradual decline of 10 to 20% over the next 8 hours.

Tobacco cell suspension cultures treated with cellulase plus varying concentrations of ancyelidol or ketoconazole were pre-incubated for 12 hours before measuring the cells’ ability to convert exogenous supplied [1H] labeled 5-epi-
aristolochene to radiolabeled capsidiol during a subsequent 3 hour incubation period (FIG. 3). Apparent activity of SEAH was inhibited in a dose-dependent manner with approximately 50% inhibition by either 25 μM acenomylid or ketoconazole, and more than 80% by 75 μM acenomylid and 95% by 100 μM ketoconazole (FIGS. 3A and B). Importantly, neither the in vitro activity of recombiant EAS nor the induction of EAS in the elicitor-treated cell cultures was significantly affected by acenomylid at concentrations as high as 100 μM (FIG. 3A). Ketoconazole also does not appear to affect the in vitro activity of EAS. However, the inducibility of cyclase activity in elicitor-treated cell extracts was inhibited by ketoconazole at concentrations above 50 μM (FIG. 3B). Therefore, the specificity of ketoconazole as an inhibitor of P450 type reactions should be assessed at or below a concentration of 50 μM under these experimental conditions.

Isolation of Elicitor-Inducible Cytochrome P450 cDNAs

A two-step approach for the isolation of candidate P450 cDNAs was followed. A PCR strategy was first employed using a directional cDNA library prepared against mRNA isolated from elicitor-induced cells as the template and degenerate PCR primers (FIG. 4). Sequence alignments of cytochrome P450s from multiple families across kingdoms were used to identify conserved regions to which a series of degenerate primers were prepared (FIGS. 4A and B). In cloning experiments, 450 to 550 bp products were expected from reactions utilizing the primer prepared to the heme-binding domain (GRXXCP(A/V)) (SEQ ID NO: 27 and 28) and the 17 vector primer (FIG. 4C). The mixtures of reaction products were shotgun cloned, and approximately 50% of the cloned PCR fragments were sequenced. About half of the sequenced DNAs contained signature sequences typical of P450 enzymes as revealed by BLAST database searches, and these corresponded to typical plant P450 family members of the CYP71, CYP73, CYP92, and CYP82 classes. Each of these PCR fragments was isolated multiple times in separate experiments. In addition, we isolated full-length cDNAs for these P450 family members. Table 1 compares the similarity and identity of the full-length cDNAs of P450 family members with those of their closest family member in the GenBank database. In addition, FIG. 8 shows an amino acid alignment of several terpene cytochrome P450s. Alignments were performed using the algorithm of the MACVECTOR software suite.

### TABLE 1

<table>
<thead>
<tr>
<th>Cytochrome P450 cDNA clone</th>
<th>Nearest relative accession number</th>
<th>% identity</th>
<th>% similarity</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP71D20</td>
<td>CYP71D7 (S. chacoense)</td>
<td>76.5</td>
<td>88.8</td>
</tr>
<tr>
<td></td>
<td>Gen EMBL U48435</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP71D21</td>
<td>CYP71D7 (S. chacoense)</td>
<td>76.3</td>
<td>88.8</td>
</tr>
<tr>
<td></td>
<td>Gen EMBL U48435</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP73A27</td>
<td>CYP73A15 (P. vulgaris)</td>
<td>79.4</td>
<td>92.6</td>
</tr>
<tr>
<td></td>
<td>Gen EMBL Y09447</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP73A28</td>
<td>CYP73A15 (P. vulgaris)</td>
<td>79.2</td>
<td>92.4</td>
</tr>
<tr>
<td></td>
<td>Gen EMBL Y09447</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP82E1</td>
<td>CYP82E1 (N. tabacum)</td>
<td>100.0</td>
<td>100.0</td>
</tr>
<tr>
<td></td>
<td>Gen EMBL AB015762</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CYP92A5</td>
<td>CYP92A3 (N. tabacum)</td>
<td>95.5</td>
<td>98.6</td>
</tr>
<tr>
<td></td>
<td>Gen EMBL X97878</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The cloned fragments were used in a second step to isolate full-length clones from the cDNA library. Screening the cDNA library by hybridization with the CYP71 and CYP73 gene fragments yielded four full-length cDNAs, two CYP71D and two CYP73A. The former clones were designated CYP71D20 and CYP71D21, and the latter were designated CYP73A27 and CYP73A28. The other two cDNA fragments corresponded to tobacco cDNAs already found in the GenBank database, CYP82E1 and CYP92A3. These two cDNAs were cloned using specific primers designed with the help of the available sequence information to amplify the full-length cDNA.

Induction of Cytochrome P450 mRNAs in Elicitor-Treated Cells

To correlate a biochemical role for P450s in sesquiterpene metabolism, RNA blot analyses were used to determine the steady-state levels of the mRNAs coding for all four of the cytochrome P450 clones and EAS in control and elicitor-treated cells (FIG. 5). The mRNAs for all four of the P450s were rapidly and transiently induced with slightly different time courses relative to one another and to the EAS mRNA. CYP73A27 mRNA, for instance, displayed an induction pattern similar to that of EAS with the maximum mRNA level occurring 9 to 12 hours after elicitation. While the EAS mRNA remained high throughout the duration of the experiment, the CYP73A27 mRNA was negligible in cells 24 hours after elicitor-treatment. In contrast, the CYP71D1 mRNA was more rapidly induced than the EAS mRNA, reached its maximum 6 to 9 hours after elicitation, and was declining by 12 hours when the EAS mRNA level was still very high.

Functional Identification of CYP71D20 as a 5-epi-aristolochene Hydrolase

To ascribe functional identity to the various P450 cDNAs, full-length cDNAs for CYP71D20, CYP82E1 and CYP92A5 were inserted into the yeast expression vector pYeDP60 (Urban et al., Biochimie 72:463-472, 1990; Pompon et al., Methods Enzymol. 272:51-64, 1996) and the expression of each in WAT11, a yeast line containing an integrated Arabidopsis thaliana cytochrome reductase gene (Pompon et al., Methods Enzymol. 272:51-64, 1996; Urban et al., J. Biol. Chem. 272: 19176-19186, 1997), was determined. Engineering the CYP73A27 cDNA required an extra modification because of an unusually long N-terminus with several hydrophilic residues that may interfere with proper intracellular targeting (Nedelkina et al., Plant Mol. Biol. 39:1079-1090, 1999). This unusual leader sequence was replaced with the membrane anchoring sequence of CYP73A1, a cinnaamate 4-hydroxylase previously demonstrated to express well in yeast (Fahrenhord and Dixon, Arch. Biochem. Biophys. 305: 509-515, 1993; Pompon et al., Methods Enzymol. 272:51-64, 1996). Expression of all these cDNAs was under the control of the glucose-repressible, galactose-inducible GAL10-CYC1 promoter (Guerente et al., Proc. Natl. Acad. Sci. U.S.A. 79:7410-7414, 1982), and expression was compared to yeast transformed with the parent pYeDP60 vector (control) alone.

After induction with galactose for approximately 16 hours, control cells and cells containing the various P450 constructs were collected, and microsomes prepared from each were analyzed for general P450 expression by CO-difference spectroscopy (Omura and Sato, J. Biol. Chem. 239:2370-2378, 1964). Microsomes prepared from cells containing the CYP71D20 (FIG. 6A) and CYP92A5 (FIG. 6B) constructs both showed characteristic CO difference spectra with peaks at 450 nm, indicating that the encoded proteins were assembling properly with their heme cofactor. Using the extinction coefficient of 91 mM⁻¹ cm⁻¹ for heme binding proteins (Omura and Sato, J. Biol. Chem. 239:2370-2378, 1964), it was determined that approximately 107 pmol of CYP71D20 and 268 pmol of CYP92A5 were expressed in the yeast cells per milligram of total yeast protein.
Both 5-epi-aristolochene and 1-deoxycapsidol were metabolized to only one product with the same retention time as capsidol. Obvious by its absence, no reaction product having a retention time similar to deoxycapsidol was detectable in the 5-epi-aristolochene incubations (FIG. 7). Co-injection of authentic capsidol with the respective reaction products resulted in a single GC peak having a 16.2 minute retention time, identical to capsidol. Mass spectra patterns for the separate reaction products were identical to that for the capsidol standard (EIMS m/z 236, 221, 203, 185, 175, 163, 157, 133, 121, 107, 93, 79, 67, 55, 43, 41).

The in vivo assay data presented in FIGS. 2 and 3 of the current work indicate that the conversion of 5-epi-aristolochene is catalyzed by at least one inducible cytochrome P450 mediated reaction.

Furthermore, any of the cytochrome p450 poly peptides described herein may include one or more hydroxylase activities which can incorporate hydroxyl groups into at least two distant sites on an isoprenoid compound. The addition of these hydroxyl groups may occur, for example, sequentially, by adding a hydroxyl group first to one site and then the other, or, in either order. Moreover, such hydroxylases may be mutated to limit their ability to hydroxylate a substrate at only one site, or, alternatively, to provide stereospecificity to their hydroxylating activity.

The above-described experiments were performed using the following materials and methods.

**Chemicals**

Standard laboratory reagents were purchased from Becton Dickinson Microbiology Systems (Sparks, Md.), FisherBiotec (Fair Lawn, N.J.) and Sigma Chemical Company (St. Louis, Mo.).

**Biological Materials and Induction Treatments**

*Nicotiana tabacum* cv. KY14 plants and cell suspension cultures were used. Cell suspension cultures were maintained in modified Murashige-Skoog (Vögeli and Chappell, Plant Physiol. 88:1291-1296, 1988). Cultures in their rapid phase of growth (3 days old) were used for all experiments. At the indicated times, cells were collected and separated from media by vacuum filtration and stored at -80°C. Induction treatments were performed by the addition of the fungal elicitors, cellulase (*Trichoderma viride*, Type RS, Onozuka) or paraceticin (*O'Donohue et al., Plant Mol. Biol. 27:577-586, 1995) at the indicated concentrations. Paraceticin was purified from *E. coli* cells overexpressing a recombinant paraceticin protein containing a carboxy-terminal histidine purification tag.

In Vivo 5-epi-aristolochene Hydroxylase Assay and Inhibition Studies

5-epi-aristolochene hydroxylase activity was measured as the incorporation of [3H]-5-epi-aristolochene into extracellular capsidol by intact cells. [3H]-5-epi-aristolochene was produced by incubating an excess of [1H]-famesol diphasate (1 μM, 20.5 Ci/mmol) with recombinant 5-epi-aristolochene synthase (Buck et al., Arch. Biochem. Biophys. 315:527-532, 1994; Rising et al., J. Am. Chem. Soc. 122: 1861-1866, 2000). The hexane extractable radioactivity from reactions was treated with a small amount of silica to remove any famesol or residual FPP before quantifying the yield of radioactive 5-epi-aristolochene by liquid scintillation counting. The hexane solvent was removed under a gentle stream of N2 gas, and the dried residue was re-dissolved in acetone. Control and elicitor-treated cells were then incubated with [3H]-5-epi-aristolochene (approximately 100,000 dpm at 2.5 nM) for 3 hour periods at various points during an induction time course before collecting the cell and media samples. Detection and quantification of capsidol in the extracellular culture media was performed as reported previously (Chappell et al., Phytochemistry 26:2225-2260, 1987), and the amount of radioactivity incorporated into capsidol was determined. For these determinations, samples were separated by TLC, and the zones corresponding to capsidol were scraped from the plate for scintillation counting.

Inhibition studies were performed by the addition of the P450 inhibitors ancymidol (Coolbaugh et al., Plant Physiol. 62:571-576, 1978; Hoshino et al., Phytochemistry 38:609-613, 1995) and ketoconazole (Hoshino et al., Phytochemistry 38:609-613, 1995; Rademaker, Annu. Rev. Plant Physiol. Plant Mol. Biol. 51:501-531, 2000) directly to the cell cultures or enzyme assay mix. Cell cultures were incubated in the presence of cellulase (0.5 μg/ml) and indicated concentrations of ancymidol or ketoconazole for 12 hours prior to the addition of [3H]-5-epi-aristolochene. After a further 3 hour incubation period, the cells or chlorellae were extracted. The amount of radioactivity incorporated into extracellular capsidol was determined as described above. To evaluate secondary effects of these inhibitors, the level of inducible sesquiterpene cyclase activity in the collected cells was determined according to (Vögeli et al., Plant Physiol. 93:182-187, 1990), as well as in vitro assays with purified recombinant EAS (Back et al., Arch. Biochem. Biophys. 315:527-532, 1994) incubated with the indicated concentrations of ancymidol and ketoconazole.

All experiments were replicated in several independent trials. While the absolute values presented may have varied between experiments by as much as 50%, the trends and time courses were consistent throughout.

**Construction of an Elicitor-Induced cDNA Library**

Cell cultures were incubated with fungal elicitor (0.5 μg cellulase/ml) for 6 hours before collecting the cells by filtration. The cells were kept frozen at -80°C until total RNA was extracted from them using Trizol (Life Technologies, Rockville, Md.) according to the manufacturer's instructions. Poly(A)* RNA was purified by two rounds of oligo(dT) cellulose column chromatography (Life Technologies, Rockville, Md.). cDNA synthesis and library construction were subsequently carried out using the UNI-ZAP XR library kit (Stratagene, La Jolla, Calif.), according to manufacturer's instructions.

**PCR Cloning Strategy**

Cytochrome P450 cDNA fragments were amplified from the elicitor-induced cDNA library using various combinations of degenerate forward and reverse primers with the vector-specific T3 and T7 primers. The template DNA was prepared from a 500 μl aliquot of the elicitor-induced cDNA library (3X10^10 pfu/μl) by heat denaturation at 70°C for 10 minutes, followed by phenol/chloroform extraction, ethanol precipitation and re-suspension in 500 μl of sterile, deionized water. Amplification reactions were performed in 50 μl volumes containing 50 mM KCl; 10 mM Tris-HCl, pH 8.8; 1.5 mM MgCl2; 200 μM of each dNTP; 2 μl template DNA; 20 pmol each of forward and reverse primer; and 1 unit Taq Polymerase (Life Technologies, Rockville, Md.). Reactions were preheated at 94°C for 2 minutes, followed by thirty-five cycles of denaturing at 94°C for 1 minute, annealing at 50°C for 1 minute 30 seconds, and polymerization at 72°C for 2 minutes. The reactions were completed by a 10-minute extension at 72°C. Aliquots of the reaction products were examined for DNA products by agarose gel fractionation, and ligated directly into the pGEM-T Easy vector (Promega, Madison, Wis.). Resulting recombinant plasmids containing insert DNAs within the expected size range were sequenced using T7 and Sp6 primers.
DNA Sequencing

All the DNA sequencing reactions were performed using the BIGDYE™ Terminator Cycle sequencing kit (Perkin-
Elmer, Wellesley, Mass.) with the sequences being read on an automated ABI Prism 310 Genetic Analyzer (Applied Bio-
systems, Foster City, Calif.). Computer assessment of the DNA sequence information was performed using the
MACVECTOR (Oxford Molecular, Madison, Wis.) software package.

cDNA Library Screening

The cDNA library was screened with digoxigenin labeled probes. A 258 bp DNA fragment amplified from the pGEM-
deg6.4 clone using gene-specific forward (5'-GGCG-GAGAATTTGCTCCTGGAAATGCTATTGGGTAG-3' (SEQ ID NO: 13)) and reverse (5'-GTACAATAGTGAGTTGAGCTAATG-3' (SEQ ID NO: 14)) primers; and a 374 bp DNA fragment amplified from the pBS-KS-CYPB3.84 clone with specific forward (5'-GGTGTGTTGAATGGACTAG-3' (SEQ ID NO: 15)) and reverse (5'-TTATGCAAGCAATTAG-
GCTGAGCAGCA-3' (SEQ ID NO: 16)) primers, were used to screen for CYP71D12. The probes were labeled with
digoxigenin-11-UTP using the PCR DIG Labeling Mix (Roche Molecular Biochemicals, Indianapolis, Ind.), hybridized
to plaque lifts of the cDNA library plated at approximately 10,000 PFUs per 150 mm plate, and was hybridization
detected with the DIG detection system according to the manufacturer’s instructions (Roche Molecular Biochemicals,
Indianapolis, Ind.). Plaques exhibiting strong hybridization were plaque purified, auto-subcloned to their plasmid forms
according to the manufacturer’s recommendations (Stratagene, La Jolla, Calif.), and then subjected to DNA sequenc-
ing as described above.

RNA Analysis

RNA gel blot analysis was carried out using 10 μg aliquots of total RNA. RNA samples were heat-denatured at 70°C for
15 minutes in sample buffer (1xMOPS, 50% formamide, 16% formaldehyde, 30% glycerol, and 3% ethidium bromide), and size fractionated on a 1.2% agarose gel containing 1xMOPS and 18.1% formaldehyde. Uniformity of sample loading was determined by visual inspection of the gel for
rRNA bands. The RNAs were then transferred to a Zeta Probe nylon membrane (Bio-Rad Laboratories, Hercules, Calif.)
and hybridized according to the manufacturer’s recommendations. Full-length cDNAs probes were labeled with [32P]-
dCTP (PRIME-IT Kit, Stratagene, La Jolla, Calif.) prior to hybridization. After hybridization, the membranes were
washed in 2xSSC/0.1% SDS once at room temperature followed by sequential washes in 0.2xSSC/0.1% SDS at 42°C.
and 65°C. Hybridization was detected with a Phosphorimager (Molecular Dynamics, model 445 SI).

Construction of yeast expression vectors

The coding regions of the P450 cDNAs were cloned into the pYEDP60 expression vector (Urban et al., J. Biol. Chem.
272:19176-19186, 1996; Pompom et al., Methods Enzymol. 272:51-64, 1996). Appropriate BamHI, EcoRI, and SstI restriction sites (underlined) were introduced via PCR primers
containing these sequences either upstream of the transla-
tion start site (ATG) or downstream of the stop codon (TAA or TGA). The primers used to amplify the CYP71D12 cDNA were
5'-GGG GGAATCCATCTTAAATCTTAAGCTTGGTCC-3' (SEQ ID NO: 17) and 5'-GGG GGAATCTACAATCTTAAGCTTGGTCC-3' (SEQ ID NO: 18), for the CYP82E1 cDNA 5'-CCC GAGAATCTCAATCTTAAGCTTGGTCC-3' (SEQ ID NO: 19) and 5'-GGG GGAATCTACAATCTTAAGCTTGGTCC-3' (SEQ ID NO: 20); and for the CYP92A3 cDNA 5'-CCC GGAATCCATCTTAAATCTTAAGCTTGGTCC-3' (SEQ ID NO: 21) and 5'-GGG GGAATCTACAATCTTAAGCTTGGTCC-3' (SEQ ID NO: 22). Two long, overlapping (tailed) primers 5'-GGCGAATCCATCTTAAATCTTAAGCTTGGTCC-3' (SEQ ID NO: 23) and 5'-GGG GGAATCTACAATCTTAAGCTTGGTCC-3' (SEQ ID NO: 24) coding for the N-terminal sequence of CYP73A1 (GenEMBL Z17369) up to the hinge
region were used for the modification of the membrane anchoring segment of CYP73A27 to avoid possible problems
with intracellular targeting due to the unusual N-terminus (Nedelkina et al., 1999); the reverse primer used for both amplifications was 5'-GGG GGAATCTACAATCTTAAGCTTGGTCC-3' (SEQ ID NO: 25). CYP71D20 and CYP73A27 were amplified using full-length cDNA templates, whereas CYP82E1 and CYP92A5 were amplified directly from the cDNA library
template. Amplifications were performed in 50 μl reactions containing 1xPfx amplification buffer, 1 mM MgSO4; 300
μM of each dNTP; 10 ng template DNA; 20 pmol each of forward and reverse primer, and 1.25 units PLATINUM® Pfx
Polymerase (Life Technologies, Rockville, Md.). Reactions were preheated at 94°C for 2 minutes, followed by thirty-five cycles of denaturing at 94°C for 15 seconds, annealing at 55°C
for 30 seconds, and elongating at 68°C for 1.5 minutes. PCR
products were ligated into the pGEM-T EASY vector (Promega, Madison, Wis.) and subcloned into the pYEDP60 vector. The resulting constructs were verified by a combination of PCR and DNA sequencing.

Yeast Expression Studies

Verified pYEDP60-P450 cDNA constructs were introduced into the yeast WAT11 line, a derivative of the W303-1B strain (MAT a; ade 2-1; his 3-11; leu 2-3,112; trp 3-1; can4-1; cys1-1), provided by Dr. P. Urban (Centre de Généétique Moleculaire, CNRS, Gif-sur-Yvette, France). The endogenous NADPH-cytochrome P450 reductase (CPR1) locus has been replaced with ATR1, a NADP1-cytochrome P450 reductase from A. thaliana (Pompon et al., Methods Enzymol. 272:51-
64, 1996; Urban et al., J. Biol. Chem. 272:19176-19186, 1997), in the WAT11 line. Yeast was grown overnight in a 30°C shaker in YPAD (1 g/l yeast extract; 1 g/l peptone; 20 g/l glucose; 200 ml/g adenine) liquid media. Cultures were harvested at an A600 between 0.5 and 1.5. Cells were collected by centrifugation at 2,500 x g for 5 minutes at 4°C, and resuspended in ice-cold, sterile dH2O. Cells were pelleted again as above and resuspended in 1 M sorbitol. Forty μl of yeast suspension was mixed with 0.5 to 1 μg plasmid DNA (in <5 μl dH2O) in a pre-chilled 0.5 ml tube, and transferred to a chilled cuvette with a 0.2 cm electrode gap. One pulse at 1.5 kV, 25 μF, and 200 Ohms was applied by an Eppendorf Electroporator (model 2510). A mixture of 500 μl of YPAD/1 M sorbitol was immediately added to the electroporated cells. Cells were allowed to recover at 30°C for 1 hour, then spread onto SGP plates (1 g/l bactocasaminic acids; 7 g/l yeast nitrogen base; 20 g/l glucose; 20 mg/l tryptophan; and 20 g/l agar). Transformed colonies appeared after 3 to 6 days of incubation at 30°C. Recombinant plasmids were confirmed by PCR assays performed directly on randomly selected yeast colonies.

For expression studies, one colony was added to SGL media (1 g/l bactocasaminic acids; 7 g/l yeast nitrogen base; 20 g/l glucose; and 20 mg/l tryptophan) and grown at 30°C for approximately 24 hours. An aliquot of this culture was diluted
1:50 into 250 ml of YPGE (10 g/l bactopeptone; 10 g/l yeast extract; 5 g/l glucose; and 3% ethanol by volume) and the cells were grown until all glucose was consumed. The absence of glucose was determined by placing a 200 µl aliquot of culture into a 1.5 ml tube, inserting a DIASTIX urinalysis reagent strip (Bayer, Elkhart, Ind.) for 30 seconds, and observing colorimetric changes indicating glucose levels. Induction was initiated by the addition of 5 grams of galactose (final concentration of 2%). The cultures were maintained at 30°C for an additional 16 hours before collecting the cells by centrifugation at 7000 x g for 10 minutes. The pelleted cells were washed with 100 ml of TES buffer (50 mM Tris-HCl pH 7.5; 1 mM EDTA; 0.6 M sorbitol). The cells were centrifuged as above, resuspended in 100 ml of TES-M (TES supplemented with 10 mM 2-mercaptoethanol), and allowed to incubate at room temperature for 10 minutes. The yeast cells were centrifuged again at 7000 x g for 10 minutes, and the pellet was resuspended in 2.5 ml extraction buffer (1% bovine serum albumin, fraction V; 2 mM 2-mercaptoethanol; 1 mM phenylmethylsulfonyl fluoride, all dissolved in TES). Glass beads (0.5-1 mm in diameter, Biospec Products, Inc., Bartlesville, Okla.) were added until the suspension of the cell suspension. Cell walls were disrupted manually by hand shaking in a cold room for 10 min at 30 second intervals separated by 30 second intervals on ice. Cell extracts were transferred to a 50 ml centrifuge tube, the glass beads were washed three times with 5 ml of extraction buffer, and the washes were pooled with the original cell extracts. Microsomes were prepared by differential centrifugation at 10,000 g for 10 minutes at 4°C, followed by centrifugation at 100,000 x g for 70 minutes at 4°C. and microsomal pellets were resuspended in 1.5 ml TEG-M buffer (50 mM Tris-HCl, pH 7.5; 1 mM EDTA; 20% glycerol; and 1.5 mM 2-mercaptoethanol) and stored frozen at -80°C until further assayed.

**CO Difference Spectra**

Fe⁺⁺ VI vs. Fe⁺⁺ VII difference spectroscopy (Omuré and Sato, J. Biol. Chem. 239:2370-2378, 1964) was performed using 0.4 ml of microsomes suspended in 1.6 ml of 50 mM Tris-HCl, pH 7.5; 1 mM EDTA; and 20% glycerol. A small amount of the reducing agent, sodium dithionite, was added, and the mixture was distributed between two cuvettes. A baseline was recorded between 400 and 500 nm on a Perkin Elmer Lambda 18 UV/Visible spectrophotometer. CO was then bubbled into the sample cuvette for 1 minute, and the difference spectrum recorded again. The amount of functional P450 was estimated based on an absorbance coefficient of 91 mM⁻¹ cm⁻¹.

**5-epi-aristolochene-1,3-hydroxylase Assays**

5-epi-aristolochene-1,3-hydroxylase assays were performed in 0.5 ml polyethylene tubes in 100 µl volumes. 5-epi-aristolochene or 1-deoxycaipsidol dissolved in hexane was added to the tube, and the organic solvent was removed by incubation of the open tube at 30°C. 5-epi-aristolochene and 1-deoxycaipsidol were resuspended in 2 µl dimethyl sulfoxide before adding the reaction mixture. Reactions were carried out in 100 mM Tris-HCl, pH 7.5, to which microsomal protein was added to a final concentration of 1 mg/ml. Reactions were initiated by the addition of 2 mM NADPH. The final concentration of 5-epi-aristolochene and 1-deoxycaipsidol in these assays varied from 20 to 50 µM. After incubations of variable lengths of time at 30°C, the reactions were extracted with two volumes of ethyl acetate. The organic extracts were concentrated and evaluated by GC and GC-MS along with standards of 5-epi-aristolochene (Whitehead et al., Phytochemistry 28:775-779, 1989; Rising et al., J. Am. Chem. Soc. 122:1861-1866, 2000), 1-deoxycaipsidol (Whitehead et al., Phytochemistry 29:479-182, 1990), and capsidiol (Whitehead et al., Phytochemistry 26:1367-1369, 1987; Milat et al., Phytochemistry 30:217-2173, 1991). GC analysis was routinely performed with an HP5890 GC equipped with a Hewlett-Packard HP-5 capillary column (30 m x 0.25 mm, 0.25 µm phase thickness) and run with He as the carrier gas (10 psi). Splitless injections were done at an injection port temperature of 280°C. The column temperature was maintained at 40°C for 1 minute and then increased to 280°C at 10°C per minute. Following separation by the GC column, samples were introduced directly into the electron impact ionization source. Mass spectra were acquired at 70 eV, scanning from 40-440 Da in 1 second.

Production of Cytochrome P450s

Using the standard molecular techniques described herein, the isolation of additional cytochrome P450 coding sequences is readily accomplished. For example, using all or a portion of the amino acid sequence of any of the disclosed P450s, one may readily design P450-specific oligonucleotide probes, including P450 degenerate oligonucleotide probes (i.e., a mixture of all possible coding sequences for a given amino acid sequence). These oligonucleotides may be based upon the sequence of either DNA strand and any appropriate portion of the P450 nucleotide sequence. General methods for designing and preparing such probes are provided, for example, in Ausubel et al., 2000, Current Protocols in Molecular Biology, Wiley Interscience, New York, and Berger and Kimmel, Guide to Molecular Cloning Techniques, 1987, Academic Press, New York. These oligonucleotides are useful for P450 gene isolation, either through their use as probes capable of hybridizing to a P450 complementary sequence, or as primers for various amplification techniques, for example, polymerase chain reaction (PCR) cloning strategies.

Hybridization techniques and screening procedures are well known to those skilled in the art and are described, for example, in Ausubel et al. (supra); Berger and Kimmel (supra); Chen et al., Arch. Biochem. Biophys. 324:255, 1995; and Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York. If desired, a combination of different oligonucleotide probes may be used for the screening of a recombinant DNA library. The oligonucleotides may be detectably-labeled using methods known in the art and used to probe filter replicates from a recombinant DNA library. Recombinant DNA libraries are prepared according to methods well known in the art, for example, as described in Ausubel et al. (supra), or they may be obtained from commercial sources.

As discussed above, P450 oligonucleotides may also be used as primers in a polymerase chain reaction (PCR) amplification cloning strategy. PCR methods are well known in the art and are described, for example, in PCR Technology, Erlich, ed., Stockton Press, London, 1989; PCR Protocols: A Guide to Methods and Applications, Inns et al., eds., Academic Press, Inc., New York, 1990; and Ausubel et al. (supra). Primers are optionally designed to allow cloning of the amplified product into a suitable vector, for example, by including appropriate restriction sites at the 5' and 3' ends of the amplified fragment (as described herein). If desired, a P450 gene may be isolated using the PCR “RACE” technique, or Rapid
Amplification of DNA Ends (see, e.g., Innis et al. (supra)). By this method, oligonucleotide primers based on a P450 sequence are oriented in the 3' and 5' directions and are used to generate overlapping PCR fragments. These overlapping 3' and 5'-end RACE products are combined to produce an intact full-length cDNA. This method is described in Innis et al. (supra) and Frohman et al., Proc. Natl. Acad. Sci. USA 85:8998, (1988).

Additional methods for identifying sequences encoding P450s are provided in Maughan et al. (Arch. Biochem. Biophys. 341:104-111, 1997) and Clark et al. (Plant Mol. Biol. 33:875-885, 1997).

Useful P450 sequences may be isolated from any appropriate organism. Confirmation of a sequence’s relatedness to a P450 polypeptide disclosed herein may be accomplished by a variety of conventional methods, for example, by comparing the sequence with a known P450 sequence found in a database. In addition, the activity of any P450 may be evaluated according to any of the techniques described herein.

P450 Polypeptide Expression

P450 polypeptides may be produced by transformation of a suitable host cell with all or part of a P450 DNA (for example, any one of the P450 cDNAs described herein) in a suitable expression vehicle or with a plasmid construct engineered for increasing the expression of a P450 polypeptide in vivo.

Those skilled in the field of molecular biology will appreciate that any of a wide variety of expression systems may be used to provide the recombinant protein. The precise host cell used is not critical to the invention. The P450 protein may be produced in a prokaryotic host, for example, E. coli TB1, or in an eukaryotic host, for example, Saccharomyces cerevisiae, insect cells, mammalian cells (for example, COS 1 or NH 3T3 cells), or any of a number of plant cells including, without limitation, algae, tree species, ornamental species, temperate fruit species, tropical fruit species, vegetable species, legume species, monocots, dicots, or in any plant of commercial or agricultural significance. Particular examples of suitable plant hosts include, but are not limited to, Conifers, Petunia, Tomato, Potato, Tobacco, Grape, Arabidopsis, Lettuce, Sunflower, Oleseed rape, Flax, Cotton, Sugarbeet, Celery, Soybean, Alfalfa, Medicago, Lotus, Vigna, Cucumber, Carrot, Eggplant, Cauliflower, Horseradish, Morning Glory, Poplar, Walnut, Apple, Aspen, Grape, Rice, Maize, Millet, Onion, Barley, Orchard grass, Oat, Rye, Tobacco, and Wheat.


For prokaryotic expression, DNA encoding a P450 polypeptide is carried on a vector operably linked to control signals capable of effecting expression in the prokaryotic host. If desired, the coding sequence may contain, at its 5' end, a sequence encoding any of the known signal sequences capable of effecting secretion of the expressed protein into the periplasmic space of the host cell, thereby facilitating recovery of the protein and subsequent purification. Prokaryotes most frequently used are various strains of E. coli; however, other microbial strains may also be used. Plasmid vectors are used which contain replication origins, selectable markers, and control sequences derived from a species compatible with the microbial host. Examples of such vectors are found in Poulwels et al. (supra) or Ausubel et al. (supra). Commonly used prokaryotic control sequences (also referred to as “regulatory elements”) are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences. Promoters commonly used to direct protein expression include the beta-lactamase (penicillinase), the lactose (lac), the tryptophan (Trp) (Goeddel et al., Nucl. Acids Res. 8:4057 (1980)), and the tac promoter systems, as well as the lambda-derived Psub.L promoter and N-gene ribosome binding site (Simatake et al., Nature 292:128 (1981)).

One particular bacterial expression system for P450 production is the E. coli pET expression system (Novagen). According to this expression system, DNA encoding a P450 is inserted into a pET vector in an orientation designed to allow expression. Since the P450 gene is under the control of the T7 regulatory signals, P450 expression is dependent on inducing the expression of T7 RNA polymerase in the host cell. This is typically achieved using host strains which express T7 RNA polymerase in response to IPTG induction. Once produced, recombinant P450 is then isolated according to standard methods known in the art, for example, those described herein.

Another bacterial expression system for P450 production is the pGEX expression system (Pharmacia). This system employs a GST gene fusion system that is designed for high-level expression of a gene or gene fragment as a fusion protein with rapid purification and recovery of the functional gene product. The P450 of interest is fused to the carboxyl terminus of the glutathione S-transferase protein from Schistosoma japonicum and is readily purified from bacterial lysates by affinity chromatography using Glutathione Sepharose 4B. Fusion proteins can be recovered under mild conditions by elution with glutathione. Cleavage of the glutathione S-transferase domain from the fusion protein is facilitated by the presence of recognition sites for site-specific proteases upstream of this domain. For example, proteins expressed in pGEX-2T plasmids may be cleaved with thrombin; those expressed in pGEX-3X may be cleaved with factor Xa.

Other prokaryotic systems useful for expressing eukaryotic P450s are described by Cooper (Mutat. Res. 454:45-52, 2000) and Dong et al. (Arch. Biochem. Biophys. 327:254-259, 1996). In addition, strategies for enhancing the prokaryotic expression of a cytochrome P450 in combination with cytochrome reductase are described in Porter et al. (Drug Metab. Rev. 31:159-174, 1999).

For eukaryotic expression, the method of transformation or transfection and the choice of vehicle for expression of the P450 will depend on the host system selected. Transformation and transfection methods of numerous organisms, for example, the baker’s yeast Saccharomyces cerevisiae, are described, e.g., in Ausubel et al. (supra); Weissbach and Weissbach, Methods for Plant Molecular Biology, Academic Press, 1989; Gelvin et al., Plant Molecular Biology Manual, Kluwer Academic Publishers, 1990; Kindle, K., Proc. Natl. Acad. Sci. U.S.A. 87:1228 (1990); Potrykus, L., Annu. Rev. Plant Physiol. Plant Mol. Biology, 42:205 (1991); and Bio-Rad (Hercules, Calif.) Technical Bulletin #1687 (Biolistic Particle Delivery Systems). Expression vehicles may be chosen from those provided, e.g., in Cloning Vectors: A Laboratory Manual (P. H. Poulwels et al., 1985, Supp. 1987); Gasser
and Fraley (supra); Clontech Molecular Biology Catalog (Catalog 1992/93 Tools for the Molecular Biologist, Palo Alto, Calif.); and the references cited above.

One preferred eukaryotic expression system is the mouse 3T3 fibroblast host cell transfected with a pMAMneo expression vector (Clontech). pMAMneo provides: an RSV-LTR enhancer linked to a dexamethasone-inducible MMTV-LTR promoter, an SV40 origin of replication which allows replication in mammalian systems, a selectable neomycin gene, and SV40 splicing and polyadenylation sites. DNA encoding a P450 is inserted into the pMAMneo vector in an orientation designed to allow expression. The recombinant P450 is then isolated as described below. Other preferable host cells which may be used in conjunction with the pMAMneo expression vehicle include COS cells and CHO cells (ATCC Accession Nos. CRL 1650 and CCL 61, respectively).

Alternatively, if desired, a P450 is produced by a stably-transfected mammalian cell line. A number of vectors suitable for stable transfection of mammalian cells are available to the public, e.g., see Pouwels et al. (supra); methods for constructing such cell lines are also publicly available, e.g., in Ausubel et al. (supra). In one example, cDNA encoding the P450 is cloned into an expression vector which includes the dihydrofolate reductase (DHFR) gene. Integration of the plasmid and, therefore, the P450-encoding gene into the host cell chromosome is selected for by inclusion of 0.01-300 μM methotrexate in the cell culture medium (as described in Ausubel et al., supra). This dominant selection can be accomplished in most cell types. Recombinant protein expression can be increased by DHFR-mediated amplification of the transfected gene. Methods for selecting cell lines bearing gene amplifications are described in Ausubel et al. (supra); such methods generally involve extended culture in medium containing gradually increasing levels of methotrexate. DHFR-containing expression vectors commonly used for this purpose include pCSEII1-DHFR and pAd326SV(A) (described in Ausubel et al., supra). Any of the host cells described above or, preferably, a DHFR-deficient CHO cell line (for example, CHO DHFR cells, ATCC Accession Number CRL 9096) are among the host cells preferred for DHFR selection of a stably-transfected cell line or DHFR-mediated gene amplification.

A cytochrome P450 may also be produced in insect cells, such cells include, without limitation, Spodoptera frugiperda (SF)-9, SF-21, or Drosophila melanogaster Schneider (SL-2) cells. For P450 production, insect cells are typically infected with a baculovirus, for example, Autographa californica Multiple Nuclear Polyhedrosis Virus (AcMNPV) containing an expression cassette for such a protein, e.g., cytochrome P450, at a multiplicity of infection of 1 to 10. The infected cells are generally cultured in a standard insect cell culture medium for 24 to 48 hours prior to recovering the protein using standard molecular biology techniques. If desired, a P450 polypeptide may also be produced in insect cells directly transfected with a DNA construct containing an expression cassette encoding the P450.

Furthermore, any of the cytochrome P450s described herein may be produced in yeast, for example, Pichia pastoris. In order to produce the P450, yeast cells are transformed with an expression cassette containing, for example, a promoter such as the AOX1 or phosphoglycerate kinase gene promoter, the P450 gene to be expressed, and a terminator. Such an expression cassette may contain an origin of replication or it may be integrated into the yeast genomic DNA. The expression cassette is generally introduced by lithium acetate transformation or by the use of spheroplasts. In order to select for successfully transformed cells, the yeast are plated, for example, on minimal media which only allows yeast carrying the introduced expression cassette to grow.

In addition, expression of recombinant proteins in yeast using a Hansenula polymorpha expression system is described in U.S. Pat. Nos. 5,741,674 and 5,672,487.

A P450 may also be produced by a stably-transfected plant cell line or by a transgenic plant. Such genetically-engineered plants are useful for a variety of industrial and agricultural applications as described below. Importantly, this invention is applicable to gymnosperms and angiosperms, and will be readily applicable to any new or improved transformation or regeneration method.

A number of vectors suitable for stable transfection of plant cells or for the establishment of transgenic plants are available to the public; such vectors are described in Pouwels et al. (supra), Weissbach and Weissbach (supra), and Gelvin et al. (supra). Methods for constructing such cell lines are described in, e.g., Weissbach and Weissbach (supra), and Gelvin et al. (supra). Typically, plant expression vectors include (1) a cloned P450 gene under the transcriptional control of 5' and 3' regulatory sequences and (2) a dominant selectable marker. Such plant expression vectors may also contain, if desired, a promoter regulatory region (for example, one conferring inducible or constitutive expression, or environmentally- or developmentally-regulated, or pathogen- or wound-inducible, or cell- or tissue-specific expression), a transcription initiation start site, a ribosome binding site, an RNA processing signal, a transcription termination site, and/or a polyadenylation signal.

The P450 DNA sequence of the invention may, if desired, be combined with other DNA sequences in a variety of ways. The P450 DNA sequence of the invention may be employed with all or part of the gene sequences normally associated with a P450. In its component parts, a DNA sequence encoding a P450 is combined in a DNA construct having a transcription initiation control region capable of promoting transcription and translation in a host cell.

In general, the constructs will involve regulatory regions functional in plants which provide for production of a P450 as discussed herein. The open reading frame coding for the P450, or a functional fragment thereof, will be joined at its 5' end to a transcription initiation regulatory region such as the sequence naturally found in the 5' upstream region of a P450 structural gene, for example, a CYP71D20 (SEQ ID NO:2) or CYP71D21 (SEQ ID NO:4) gene. Numerous other transcription initiation regions are available which provide for constitutive or inducible regulation.

For applications when developmental, cell, tissue, hormonal, environmental, or pathogen-inducible expression are desired, appropriate 5' upstream non-coding regions are obtained from other genes; for example, from genes regulated during seed development, embryo development, leaf development, or in response to a pathogen.

Regulatory transcript termination regions may also be provided in DNA constructs of this invention as well. Transcript termination regions may be provided by the DNA sequence encoding a P450 or any convenient transcription termination region derived from a different gene source. The transcript termination region will contain preferably at least 1-3 kb of sequence 3' to the structural gene from which the termination region is derived.

An example of a useful plant promoter according to the invention is a caulimovirus promoter, such as, a cauliflower mosaic virus (CaMV) promoter. These promoters confer high levels of expression in most plant tissues, and the activity of these promoters is not dependent on virally encoded proteins. CaMV is a source for both the 35S and 19S promoters. In
most tissues of transgenic plants, the CaMV 35S promoter is a strong promoter (see, e.g., Odell et al., Nature 313:810 (1985)). The CaMV promoter is also highly active in monocots (see, e.g., Dekeyser et al., Plant Cell 2:591 (1990); Terada and Shimamoto, Mol. Gen. Genet. 220:389, (1990)). Moreover, activity of this promoter can be further increased (i.e., between 2-10 fold) by duplication of the CaMV 35S promoter (see, e.g., Kay et al., Science 236:1290 (1987); Ow et al., Proc. Natl. Acad. Sci. U.S.A. 84:4870 (1987); and Fang et al., Plant Cell 1:141 (1989)). Other useful plant promoters include, without limitation, the nopaline synthase promoter (An et al., Plant Physiol. 88:547 (1988)) and the octopine synthase promoter (Fromm et al., Plant Cell 1:977 (1989)).

For certain applications, it may be desirable to produce the P450 gene product in a appropriate tissue, at an appropriate level, or at an appropriate developmental time. For this purpose, there is an assortment of gene promoters, each with its own distinct characteristics, embodied in its regulatory sequences, which have been shown to be regulated in response to the environment, hormones, and/or developmental cues. These include gene promoters that are responsible for heat-regulated gene expression (see, e.g., Callis et al., Plant Physiol. 88:965 (1988); Takahashi and Komeda, Mol. Gen. Genet. 219:365 (1989); and Takahashi et al., Plant J. 2:751 (1992)), light-regulated gene expression (e.g., the pea rbcS-3A described by Kuhlmeier et al. (Plant Cell 1:471 (1989)); the maize rbcS promoter described by Schaffner and Sheen, (Plant Cell 3:997 (1991)) or the chlorophyll-abd-binding protein gene found in pea described by Simpson et al. (EMBO J. 4:2723 (1985)), hormone-regulated gene expression (for example, the abscisic acid (ABA) responsive sequences from the Em gene of wheat described by Marcotte et al. (Plant Cell 1:969 (1989)); the ABA-inducible HVA1 and HVA22, and the nd29A promoters described for barley and Arabidopsis by Straub et al. (Plant Cell 6:617 (1994), Shen et al. (Plant Cell 7:295 (1994)), and wound-induced gene expression (for example, wun described by Siebertz et al. (Plant Cell 1:961 (1989)), or organ-specific gene expression (for example, of the tuber-specific storage protein gene described by Roshul et al. (EMBO J. 6:1155 (1987)), the 23-kDa zein gene from maize described by Scherthaner et al. (EMBO J. 7:1249 (1988)); or the French bean beta-phaseolin gene described by Bustos et al., (Plant Cell 1:839 (1989)); and pathogen-inducible gene expression described by Chappell et al. in U.S. Ser. Nos. 08/471,983, 08/443,639, and 08/577,483, hereby incorporated by reference.

Plant expression vectors may also optionally include RNA processing signals, for example, introns, which have been shown to be important for efficient RNA synthesis and accumulation (Callis et al., Genes and Dev. 1:1183 (1987)). The location of the RNA splice sequences can dramatically influence the level of transgene expression in plants. In view of this fact, an intron may be positioned upstream or downstream of a P450-encoding sequence in the transgene to modulate levels of gene expression.

In addition to the aforementioned 5′ regulatory control sequences, the expression vectors may also include regulatory control regions which are generally present in the 3′ regions of plant genes (Thornburg et al., Proc. Natl. Acad. Sci. U.S.A. 84:744 (1987); An et al., Plant Cell 1:115 (1989)). For example, the 3′ terminator region may be included in the expression vector to increase stability of the mRNA. One such terminator region may be derived from the PI-II terminator region of potato. In addition, other commonly used terminators are derived from the octopine or nopaline synthase signals.

The plant expression vector also typically contains a dominant selectable marker gene used to identify those cells that have been transformed. Useful selectable genes for plant systems include genes encoding antibiotic resistance genes, for example, those encoding resistance to hygromycin, kanamycin, bleomycin, G418, streptomycin, or spectinomycin. Genes required for photosynthesis may also be used as selectable markers in photosynthetic-deficient strains. Alternatively, the green-fluorescent protein from the jellyfish Aequorea victoria may be used as a selectable marker (Sheen et al., Plant J. 8:777, 1995; Chiu et al., Current Biology 6:325 (1996)). Finally, genes encoding herbicide resistance may be used as selectable markers; useful herbicide resistance genes include the bar gene encoding the enzyme phosphinotricin acetyltransferase and conferring resistance to the broad-spectrum herbicide BASTA (Hoechst AG, Frankfurt, Germany).

Efficient use of selectable markers is facilitated by a determination of the susceptibility of a plant cell to a particular selectable agent and a determination of the concentration of this agent which effectively kills most, if not all, of the transformed cells. Some useful concentrations of antibiotics for tobacco transformation include, e.g., 75-100 μg/ml (kanamycin), 20-50 μg/ml (hygromycin), or 5-10 μg/ml (bleomycin). A useful strategy for selection of transformants for herbicide resistance is described, e.g., by Vasil et al., supra.

It should be readily apparent to one skilled in the art of molecular biology, especially in the field of plant molecular biology, that the level of gene expression is dependent, not only on the combination of promoters, RNA processing signals, and terminator elements, but also on how these elements are used to increase the levels of selectable marker gene expression.

Plant Transformation

Upon construction of the plant expression vector, several standard methods are available for introduction of the vector into a plant host, thereby generating a transgenic plant. These methods include (1) Agrobacterium-mediated transformation (A. tumefaciens or A. rhizogenes) (see, e.g., Lichtenstein and Fuller, In: Genetic Engineering, vol. 6, P W J Rigby, ed, London, Academic Press, 1987; and Lichtenstein, C. P., and Draper, J., In: DNA Cloning, Vol II, D. M. Glover, ed, Oxford, IRL Press, 1985), (2) the particle delivery system (see, e.g., Gordon-Kamm et al., Plant Cell 2:603 (1990); or BioRad Technical Bulletin 1687, supra), (3) microinjection protocols (see, e.g., Green et al., supra), (4) polyethylene glycol (PEG) procedures (see, e.g., Draper et al., Plant Cell Physiol. 23:451 (1982); or e.g., Zhang and Wu, Theor. Appl. Genet. 76:835 (1988)), (5) liposome-mediated DNA uptake (see, e.g., Freeman et al., Plant Cell Physiol. 25:1353 (1984)), (6) electroporation protocols (see, e.g., Gelvin et al., supra; Dekeyser et al., supra; Fromm et al., Nature 319:791 (1986); Sheen, Plant Cell 2:1027 (1990); and Jang and Sheen, Plant Cell 6:1665 (1994)), and (7) the vortexing method (see, e.g., Kindle, supra). The method of transformation is not critical to the present invention. Any method which provides for efficient transformation may be employed. As newer methods are available to transform crops or other host cells, they may be directly applied.

The following is an example outlining one particular technique, an Agrobacterium-mediated plant transformation. By this technique, the general process for manipulating genes to be transferred into the genome of plant cells is carried out in two phases. First, cloning and DNA modification steps are carried out in E. coli, and the plasmid containing the gene construct of interest is transferred by conjugation or electroporation into Agrobacterium. Second, the resulting Agrobacterium strain is used to transform plant cells. Thus, for the
generalized plant expression vector, the plasmid contains an origin of replication that allows it to replicate in Agrobacterium and a high copy number origin of replication functional in E. coli. This permits facile production and testing of transgenes in E. coli prior to transfer to Agrobacterium for subsequent introduction into plants. Resistance genes can be carried on the vector, one for selection in bacteria, for example, streptomycin, and another that will function in plants, for example, a gene encoding kanamycin resistance or herbicide resistance. Also present on the vector are restriction endonuclease sites for the addition of one or more transgenes and directional T-DNA border sequences which, when recognized by the transfer functions of Agrobacterium, delimit the DNA region that will be transferred to the plant.

In another example, plant cells may be transformed by shooting into the cell tungsten microprojectiles on which cloned DNA is precipitated. In the Biolistic Apparatus (Bio-Rad) used for the shooting, a gunpowder charge (22 caliber Power Piston Tool Charge) or an air-driven blast drives a plastic macroprojectile through a gun barrel. An aliquot of a suspension of tungsten particles on which DNA has been precipitated is placed on the front of the plastic macroprojectile. The latter is fired at an acrylic stopping plate that has a hole through it that is too small for the macroprojectile to pass through. As a result, the plastic macroprojectile smashes against the stopping plate, and the tungsten microprojectiles continue toward their target through the hole in the plate. For the present invention, the target can be any plant cell, tissue, seed, or embryo. The DNA introduced into the cell on the microprojectiles becomes integrated into either the nucleus or the chloroplast.

In general, transfer and expression of transgenes in plant cells are now routine practices to those skilled in the art, and have become major tools to carry out gene expression studies in plants and to produce improved plant varieties of agricultural or commercial interest.

Transgenic Plant Regeneration

Plants cells transformed with plant expression vectors can be regenerated, for example, from single cells, callus tissue, or leaf discs according to standard plant tissue culture techniques. It is well known in the art that various cells, tissues, and organs from almost any plant can be successfully cultured to regenerate an entire plant; such techniques are described, e.g., in Usisil supra; Green et al., supra; Weitsbach and Weitsbach, supra; and Gelvin et al., supra.

In one particular example, a cloned P450, under the control of the EAS4 promoter and the nopaline synthase terminator and carrying a selectable marker (for example, kanamycin resistance), is transformed into Agrobacterium. Transformation of leaf discs (for example, of tobacco leaf discs), with vector-containing Agrobacterium is carried out as described by Horsch et al. (Science 227:1229 (1985)). Putative transformants are selected after a few weeks (for example, 3 to 5 weeks) on plant tissue culture media containing kanamycin (e.g., 100 μg/ml). Kanamycin-resistant shoots are then placed on plant tissue culture media without hormones for root initiation. Kanamycin-resistant plants are then selected for greenhouse growth. If desired, seeds from self-fertilized transgenic plants can then be sown in soil-less medium and grown in a greenhouse. Kanamycin-resistant progeny are selected by sowing surface sterilized seeds on hormone-free kanamycin-containing media. Analysis for the integration of the transgene is accomplished by standard techniques (see, for example, Ausubel et al., supra; Gelvin et al., supra).

Transgenic plants expressing the selectable marker are then screened for transmission of the transgene DNA by standard immunoblot and DNA detection techniques. Each positive transgenic plant and its transgenic progeny is unique in comparison to other transgenic plants established with the same transgene. Integration of the transgene DNA into the plant genomic DNA is in most cases random, and the site of integration can profoundly affect the levels and the tissue and developmental patterns of transgene expression. Consequently, a number of transgenic lines are usually screened for each transgene to identify and select plants with the most appropriate expression profiles.

Transgenic lines are generally evaluated for levels of transgene expression. Expression at the RNA level is determined initially to identify and quantitate expression-positive plants. Standard techniques for RNA analysis are employed and include PCR amplification assays using oligonucleotide primers designed to amplify only transgene RNA templates and solution hybridization assays using transgene-specific probes (see, e.g., Ausubel et al., supra). The RNA-positive plants are then analyzed for protein expression by Western immunoblot analysis using specific antibodies to the P450 (see, e.g., Ausubel et al., supra). In addition, in situ hybridization and immunocytochemistry according to standard protocols can be done using transgene-specific nucleotide probes and antibodies, respectively, to localize sites of expression within transgenic tissue.

Once the recombinant P450 is expressed in any cell or in a transgenic plant (for example, as described above), it may be isolated, e.g., using affinity chromatography. In one example, an anti-P450 antibody (e.g., produced as described in Ausubel et al., supra, or by any standard technique) may be attached to a column and used to isolate the polypeptide. Lysis and fractionation of P450-producing cells prior to affinity chromatography may be performed by standard methods (see, e.g., Ausubel et al., supra). Once isolated, the recombinant protein can, if desired, be further purified, for example, by high performance liquid chromatography (see, e.g., Fisher, Laboratory Techniques in Biochemistry and Molecular Biology, eds., Work and Burdon, Elsevier, 1980).

These general techniques of polypeptide expression and purification can also be used to produce and isolate useful P450 fragments or analogs.

Use

The aforementioned cytochrome P450 polypeptides of the invention are useful in the biosynthesis of hormones, lipids, and secondary metabolites, and may also help plants tolerate potentially harmful exogenous chemicals such as herbicides, pesticides, and pollutants. In addition, such cytochrome P450 polypeptides are useful in the chemical defense of plants against insects, as well as against bacterial, viral, and fungal infection.

Engineering Plant Disease Resistance

Plasmid constructs designed for the expression of a P450 gene product are useful, for example, for activating plant defense pathways that confer anti-pathogenic properties to a transgenic plant, for example, the production of phytoalexins. P450 genes that are isolated from a host plant (e.g., Nicotiana) may be engineered for expression in the same plant, a closely related species, or a distantly related plant species. For example, a P450 gene may be engineered for constitutive low-level expression and then transformed into a Nicotiana host plant. Alternatively, the P450 gene may be engineered for expression in other solanaceous plants, including, but not limited to, potato and tomato. To achieve pathogen resistance, it is important to express a P450 protein at an effective level. Evaluation of the level of pathogen protection conferred to a
plant by ectopic expression of the P450 gene is determined according to conventional methods and assays.

INDUSTRIAL APPLICATIONS

The invention also includes engineering host cells to include novel isoprenoid metabolic pathways useful in the production of new isoprenoid compounds. By introducing genes encoding an isoprenoid synthase (as disclosed in U.S. Pat. No. 5,824,774 and WO 00/017327) and a cytochrome P450, an acetyltransferase, a methyl transferase, a fatty acyltransferase, or a combination thereof, various isoprenoid reaction products may be modified, controlled, or manipulated, resulting in enhancement of production of numerous isoprenoid reaction products, for example, the production of novel monoterpenes, diterpenes, and sesquiterpenes. Such compounds are useful as phytoalexins, insecticides, perfumes, and pharmaceuticals such as anti-bacterial and fungal agents.

In one working example, an isoprenoid synthase or a chimeric isoprenoid synthase (as disclosed in U.S. Pat. No. 5,824,774 and WO 00/017327) are used to express a P450 gene into yeast, for example, using any of the procedures described herein. If desired, such cells may also express, either independently or in combination, an acetyltransferase (see, for example, Walker et al., Proc. Natl. Acad. Sci. USA 18:583-587, 2000), a methyle transferase (see, for example, Diener et al., Plant Cell 12:853-870, 2000) gene, or a fatty acyltransferase gene, as well as a cytochrome reductase. Cells are then cultured under standard conditions and the production of isoprenoid compounds is assayed according to methods known in the art. Isoprenoid compounds are further purified according to methods well known in the art. Cells expressing novel isoprenoid compounds are taken as useful in the invention.

Such methods provide a unique approach for producing novel isoprenoid starting materials and end products. Either prokaryotic or eukaryotic cells transformed with any of the aforementioned enzymes (or combinations thereof) may be used. Moreover, isoprenoid compounds may be produced in any number of ways known in the art including an in vitro combination of purified enzymes with an appropriate substrate or direct fermentation using a host cell which expresses any combination of the aforementioned enzymes and the appropriate substrates sufficient to drive production of isoprenoid compounds.

The invention is also useful for the production of insect attractants and deterrents, which may either deter insect pests or attract insect predators. In addition, the invention is also useful for generating novel flavorings and perfumes.

Other Embodiments

From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, other embodiments are also within the claims.

All publications and patents mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent was specifically and individually indicated to be incorporated by reference.

SEQ LISTING

<160> NUMBER OF SEQ ID NOS: 43
<210> SEQ ID NO 1
<211> LENGTH: 473
<212> TYPE: PRT
<213> ORGANISM: Nicotiana tabacum
<400> SEQUENCE:

Met Glu Phe Phe Ser Leu Val Ser Ile Phe Leu Phe Leu Ala Phe Leu 1 5 10
Phe Leu Leu Arg Lys Trp Lys Asn Ser Asn Ser Glu Ser Lys Lys Leu 20
Pro Pro Gly Pro Trp Lys Ile Pro Ile Leu Gly Ser Met Leu His Met 30
Ile Gly Gly Glu Pro His His Val Leu Arg Asp Leu Ala Lys Lys Tyr 40
Gly Pro Leu Met His Leu Glu Leu Gly Ile Ser Ala Val Val Val 50
Thr Ser Arg Asp Met Ala Lys Glu Val Leu Lys Thr His Asp Val 60
Thr Ser Arg Asp Pro Lys Val Ala Met Asp Ile Ile Cys Tyr Asn 70
Phe Ala Ser Arg Pro Lys Val Ala Met Asp Ile Ile Cys Tyr Asn 80
Gln Ser Asp Ile Ala Phe Ser Pro Tyr Gly Asp His Trp Arg Glu Met 90
Arg Lys Ile Cys Val Met Glu Leu Leu Asn Ala Lys Asn Val Arg Ser 100
Phe Ser Ser Ile Arg Arg Asp Glu Val Val Arg Leu Ile Asp Ser Ile 110
Arg Ser Asp Ser Ser Gly Glu Leu Val Asn Phe Thr Glu Arg Ile
145 150 155 160
Ile Trp Phe Ala Ser Ser Met Thr Cys Arg Ser Ala Phe Gly Glu Val
165 170 175
Leu Lys Gly Glu Asp Ile Phe Ala Lys Ile Arg Glu Val Ile Gly
180 185 190
Leu Ala Glu Gly Phe Asp Val Val Asp Ile Phe Pro Thr Tyr Lys Phe
195 200 205
Leu His Val Leu Ser Gly Met Lys Arg Lys Leu Leu Asn Ala Asp Leu
210 215 220 225 230 235
Lys Val Asp Ala Ile Val Glu Asp Val Ile Asn Glu His Lys Asn
240 245 250 255
Leu Ala Ala Gly Lys Ser Asn Gly Ala Leu Glu Asp Met Phe Ala Ala
260 265 270
Gly Thr Glu Thr Ser Ser Thr Thr Val Trp Ala Met Ala Glu Met
275 280 285
Met Lys Asp Asp Val Glu Lys Ala Gln Ala Glu Val Arg Glu
290 295 300
Ser Pro Ser Ala Glu Asp Lys Arg Val Asp Asp Glu Asp Val Glu Glu Leu
305 310 315 320
Lys Tyr Leu Lys Leu Val Ile Lys Glu Thr Leu Arg Leu His Pro Pro
325 330 335
Ser Pro Leu Leu Val Pro Arg Glu Cys Arg Glu Asp Thr Asp Ile Asn
340 345 350
Gly Tyr Thr Ile Pro Ala Lys Thr Tyr Val Met Val Asn Val Trp Ala
355 360 365
Leu Gly Arg Asp Pro Lys Tyr Trp Asp Ala Glu Ser Phe Lys Pro
370 375 380
Glu Arg Phe Gly Glu Cys Ser Val Asp Phe Gly Asp Asn Phe Glu
385 390 395 400
Phe Leu Pro Phe Gly Gly Arg Arg Ile Cys Pro Gly Met Ser Phe
405 410 415
Gly Ala Ala Pro Ala Tyr Ser Ala Tyr Ser Ala Glu Leu Leu Tyr His Phe
420 425 430
Asp Trp Lys Leu Pro Thr Gly Ile Met Pro Arg Asp Leu Asp Leu Thr
435 440 445
Glu Leu Ser Gly Ile Thr Ile Ala Arg Lys Gly Leu Tyr Leu Asn
450 455 460
Ala Thr Pro Tyr Gln Pro Ser Arg Glu
465 470
<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>25</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>40</td>
<td>45</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>55</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>65</td>
<td>70</td>
<td>75</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>80</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>95</td>
<td>90</td>
<td>95</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>100</td>
<td>105</td>
<td>110</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>115</td>
<td>120</td>
<td>125</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>130</td>
<td>135</td>
<td>140</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<210> SEQ ID NO 4
<211> LENGTH: 1614
<212> TYPE: DNA
<213> ORGANISM: Nicotiana tabacum
<400> SEQUENCE: 4

ggatggtcga ataatcttcc atttatctcc csaatgggaa ttcttcagct tggatccat
attctattcc ctatctttcc totttttggt aaggaatgt aagaacttca atagccaaac
casacaattg ctctccaggtc catgggaat accaatcact ggaagtattgc ttcatagct
tggtagggaa cacacacaca tctcttagga tttagccaaa aataatggac caattaacyc

Phe Ser Ser Ile Arg Arg Glu Val Val Arg Leu Ile Asp Ser Ile 145
Arg Ser Asp Ser Ser Gly Glu Leu Val Asn Phe Thr Glu Arg Ile 165
Ile Trp Phe Ala Ser Ser Met Thr Cys Arg Ser Ala Phe Gly Glu Ven 185
Leu Lys Gly Gln Asp Val Phe Ala Lys Lys Ile Arg Glu Val Ile Gly 195
Leu Ala Glu Gly Phe Asp Val Ala Asp Ile Phe Pro Ser Tyr Lys Phe 210
Leu His Val Leu Ser Gly Met Lys Arg Lys Leu Leu Asn Ala His Leu 225
Lys Val Asp Ala Ile Val Glu Asp Val Ile Asn Glu His Lys Asn 245
Leu Ala Thr Gly Lys Thr Asn Gly Ala Leu Gly Glu Asp Met Phe Ala 260
Ala Gly Thr Glu Thr Ser Ser Thr Thr Thr Val Trp Ala Met Ala Glu 275
Met Met Lys Asn Pro Asn Val Phe Asn Lys Ala Gin Ala Glu Val Arg 290
Glu Thr Phe Lys Asp Lys Val Thr Phe Asp Glu Ile Asp Ala Glu Glu 305
Leu Glu Tyr Leu Lys Leu Val Ile Lys Glu Thr Leu Arg Leu His Pro 325
Pro Ser Pro Leu Leu Val Pro Arg Glu Cys Arg Glu Asp Thr Asp Ile 340
Asn Gly Tyr Thr Ile Pro Ala Lys Thr Lys Val Met Val Asn Val Trp 355
Ala Leu Gly Arg Asp Pro Lys Tyr Trp Asp Asp Ala Glu Ser Phe Lys 370
Pro Glu Arg Phe Glu Gln Cys Ser Val Asp Phe Phe Gly Asn Phe 385
Glu Phe Leu Pro Phe Gly Gly Gly Arg Arg Ile Cys Pro Gly Met Ser 405
Phe Gly Leu Ala Asn Leu Tyr Leu Pro Leu Ala Gin Leu Leu Tyr His 420
Phe Asp Trp Lys Leu Pro Ser Gly Met Met Pro Gly Asp Leu Asp Leu 435
Thr Glu Leu Ala Gly Ile Thr Ile Ala Arg Lys Gly Asp Leu Tyr Leu 450
Met Ala Thr Pro Tyr Glu Pro Ser Arg Glu 465

470
ccttcagttt ggtgaaattt ctgcagttgt ggttacctct aagggagatgg caaaagaagt
300
gctaaaaacct catgacagtct ttttgctatc taggccgata atttggaacc tggatctat
360
cctttataac cagctgttga tcggctttgc cccctcaaggg gacaaacagctg
420	taaaatttgc gctcaggtgac tttcttaaatg aagaatgattt ctgtttctca gctgttctag
480
taaaggtgaa gtcgctttgc tctttgacttc tattttgaca gatttttttcctgcttgatgct
540	agttatatttt aggcaactgct tcatattttg gtaggtccca atgaacgtta gtagactat
600
ttgccgaagtt cttaaggggc aagctgtattt tgccaagaag attagagaag tataaggtgt
660
tagagaaggg ctctgagcttg cctatccttac aacatcttc tattttttctgctttctag
720
tgtgaatagag cgtaacacttc tgaatgcccc cctttaggta gatgcatcatt tggagaggtg
780
catcaacaggt ccacaagaaa atctttgcaac tggcaaaaat aaggtcgat ctagagcat
840
gttgctgctc ggacagaaaa cttctcatcaac aacaagctca tgggctatgc gtaaatgagta
900
gagaagtctc aattttttaa aacaaagttc gggggagtcag aaagggact ctaaacaaaac
960
tgtagaactcc aggtaatgctgctatattc gttgctgat ctaaatgtcgtcctctgattcagtttctg
1020
taggtctggac gtttttggat gtaataatttt tggattatttc cccctttttgttggcagttttg
1080
tggagaagat ccacaatttg ggtgaaagtc gcacaagattt aagggctagct gttgcttcat
1140
tagttgattgt gtttggattgta tctatattttttt cctttgtgctg cttgctttctc
1200
aatgattcct ggttagttcg tttgttttac ttgocattgg ccttaattgtc
1260
tatcatcct tgggaaacc cccccagcaggg gatgtgctgtc ggagcttgtt gtagctgtgt
1320
attagctgga atageacagt gtagaatgggg tggccctagtt cttatggtgct ctctctctctct
1380
aatctttgct gaaaaattaat ctagaatcag gttttttttt tcaattttgc ctaacgctct
1440
attgtaagctt tctctttcttgt ttcttttttgtt attttttttttttttt
1500
tagataacat cctcaggtct aagggagaca ttaattttctt gtaaaaaaaa aaaa
1560
1614

<210> SEQ ID NO 5
<211> LENGTH: 537
<212> TYPE: PRO
<213> ORGANISM: Nicotiana tabacum
<400> SEQUENCE: 5

Met Lys Arg Met Ala Lys Leu Leu Arg Lys Thr Ile Phe Cys Ile Leu
1  5  10  15
Fhe Thr Ile Ala Phe Leu Ser Phe Ala Lys Leu Leu Ser Ser Tyr Leu
20 25 30
Ser Met Pro Phe Pro Leu Lys Tyr Met Ser Leu Ile Val Pro Leu Leu
35 40 45
Pro Leu Ile Ile Ann Phe Leu Tyr Val Gly Ann Ann Ann Leu Pro
50 55 60
Pro Gly Pro Thr Ala Val Pro Ile Phe Gly Ann Trp Leu Gln Val Gly
65 70 75 80
Ann Asp Leu Ann His Gly Leu Ala Thr Met Ser Gln Thr Tyr Gly
85 90 95
Pro Ile Phe Leu Leu Lys Leu Gly Ser Lys Ann Leu Ala Val Val Ser
100 105 110
Ann Pro Glu Leu Leu Ala Asp Gln Val Leu His Thr Gly Val Glu Phe
115 120 125
Gly Ser Arg Pro Arg Ann Val Val Phe Asp Ile Phe Thr Gly Ann Gly
130 135 140
Gln Asp Met Val Phe Thr Ile Tyr Gly Asp His Trp Arg Lys Met Arg
145 150 155 160
Arg Ile Met Thr Leu Pro Phe Phe Thr Asn Lys Val Val His Gln Tyr
165 170 175
Ser Asp Met Trp Glu Asn Glu Met Asp Leu Val Val Asn Asp Leu Lys
180 185 190
Lys Asn Glu Lys Val Lys Tyr Glu Gly Ile Val Ile Arg Lys Arg Leu
195 200 205
Gln Leu Met Leu Tyr Asn Ile Met Tyr Arg Met Met Phe Asp Ala Lys
210 215 220
Phe Glu Ser Glu Asn Asp Pro Leu Phe Ile Glu Ala Thr Lys Phe Asn
225 230 235 240
Ser Glu Arg Ser Arg Leu Ala Gln Ser Phe Asp Tyr Asn Tyr Gly Asp
245 250 255
Phe Ile Pro Leu Leu Arg Pro Phe Leu Arg Gly Tyr Leu Asn Lys Cys
260 265 270
Lys Asp Leu Gln Thr Arg Arg Leu Ala Phe Phe Asn Asn Tyr Phe Val
275 280 285
Glu Lys Arg Arg Lys Ile Met Asp Glu Asn Gly Lys His Lys Ile
290 295 300
Ser Cys Ala Ile Asp His Ile Ile Asp Ala Glu Met Lys Gly Glu Ile
305 310 315 320
Asn Glu Gln Asn Val Leu Tyr Ile Val Glu Asn Ile Asn Val Ala Ala
325 330 335
Ile Glu Thr Thr Leu Trp Ser Met Glu Trp Ala Ile Ala Glu Leu Val
340 345 350
Asn His Pro Ile Val Gln Gln Lys Ile Arg Asp Glu Ile Ser Thr Val
355 360 365
Leu Lys Gly Arg Ser Val Thr Glu Ser Asn Leu His Glu Leu Pro Tyr
370 375 380
Leu Leu Ala Thr Val Asn Glu Thr Leu Arg Leu His Thr Pro Ile Pro
385 390 395 400
Leu Leu Val Pro His Met Asn Leu Glu Ala Lys Leu Gly Gly Tyr
405 410 415
Thr Ile Pro Lys Glu Thr Lys Val Val Asn Ala Trp Trp Leu Ala
420 425 430
Asn Asn Pro Ala Trp Trp Lys Asn Pro Asn Glu Phe Arg Pro Glu Arg
435 440 445
Phe Leu Glu Glu Asp Ser Ser Thr Glu Ala Val Ala Gly Gly Lys
450 455 460
Val Asp Phe Arg Tyr Leu Pro Phe Gly Met Gly Arg Arg Ser Cys Pro
465 470 475 480
Gly Ile Ile Leu Ala Leu Pro Ile Leu Gly Leu Val Ile Ala Lys Leu
485 490 495
Val Ser Asn Phe Glu Met Glu Gly Pro Pro Gly Val Glu Lys Val Asp
500 505 510
Thr Ser Glu Arg Gly Gly Phe Ser Leu His Ile Ala Lys His Ser
515 520 525
Thr Val Val Phe Lys Pro Ile Ala Ala
530 535

<210> SEQ ID NO 6
<211> LENGTH: 1745
<212> TYPE: DNA
<210> SEQ ID NO 7
<211> LENGTH: 534
<212> TYPE: PRT
<213> ORGANISM: Nicotiana tabacum

<400> SEQUENCE: 7

Met Ala Lys Leu Leu Asn Asn Thr Ile Phe Cys Ile Leu Phe Ser Ile

Val Phe Leu Ser Phe Ala Lys Leu Leu Ser Ser Tyr Leu Ser Ile Pro

Phe Pro Leu Glu Tyr Ile Ser Leu Ile Val Leu Leu Leu Pro Leu Ile
Ile Asn Phe Leu Cys Val Lys Pro Gln Asn Asn Leu Pro Pro Gly Pro
50  55  60
Thr Ala Val Pro Ile Phe Gly Asn Trp Leu Gln Val Gly Asn Asp Leu
65  70  75  80
Asn His Gln Leu Ala Thr Met Ser Gln Thr Tyr Gly Pro Ile Phe
85  90  95
Leu Leu Lys Leu Gly Ser Lys Asn Leu Ala Val Ser Asn Pro Phe
100 105 110
Leu Ala Asn Gln Val Leu His Thr Gln Gly Val Gly Phe Gly Ser Arg
115 120 125
Pro Arg Asn Val Val Phe Asp Ile Phe Thr Gly Asn Gly Gin Asp Met
130 135 140
Val Phe Thr Ile Tyr Gly Asp His Trp Arg Lys Met Arg Arg Ile Met
145 150 155 160
Thr Leu Pro Phe Thr Asn Val Val His Gin Tyr Ser Asp Met
165 170 175
Trp Glu Asn Glu Met Asp Leu Val Val Asp Asp Leu Lys Gin Lys Glu
180 185 190
Lys Val Lys Tyr Asp Gly Ile Val Ile Arg Lys Arg Leu Gin Leu Met
195 200 205
Leu Tyr Asn Ile Met Tyr Arg Met Met Phe Asp Ala Lys Phe Glu Ser
210 215 220
Gln Asp Asp Pro Leu Phe Ile Glu Ala Thr Lys Phe Asn Ser Glu Arg
225 230 235 240
Ser Arg Leu Ala Gin Ser Phe Asp Tyr Asn Tyr Gly Asp Phe Ile Pro
245 250 255
Leu Leu Arg Pro Phe Leu Lys Gly Tyr Leu Asn Lys Cys Lys Asp Leu
260 265 270
Gln Thr Arg Arg Leu Ala Phe Asn Asn Tyr Phe Val Gly Lys Arg
275 280 285
Arg Lys Ile Met Gly Glu Asn Gly Glu Lys His Lys Ile Cys Cys Ala
290 295 300
Ile Asp His Ile Ile Asp Ala Glu Met Lys Gly Glu Ile Ser Glu Gin
305 310 315 320
Asn Val Leu Tyr Ile Val Glu Asn Ile Asn Ala Ala Asl Glu Thr
325 330 335
Thr Leu Trp Ser Met Glu Trp Ala Ala Glu Leu Val Asn His Pro
340 345 350
Ile Val Gin Gin Lys Ile Arg Asp Glu Ile Ser Thr Val Leu Lys Gly
355 360 365
Lys Ser Val Lys Glu Ser Asn Leu His Glu Leu Pro Tyr Leu Leu Ala
370 375 380
Thr Val Asn Glu Thr Leu Arg Leu His Thr Pro Ile Pro Leu Leu Val
385 390 395 400
Pro His Met Asn Leu Glu Ala Lys Leu Gly Gly Tyr Thr Ile Pro
405 410 415
Lys Glu Thr Lys Val Val Asn Ala Trp Trp Leu Ala Asn Asn Pro
420 425 430
Ala Trp Trp Lys Asn Gin Asn Glu Phe Arg Pro Glu Arg Phe Leu Glu
435 440 445
Glu Asp Ser Ser Thr Glu Ala Ala Val Ala Gly Lys Val Asp Phe
450 455 460
Arg Tyr Leu Pro Phe Gly Met Gly Arg Arg Ser Cys Pro Gly Ile Ile
Leu Ala Leu Pro Ile Leu Gly Leu Val Ile Ala Lys Leu Val Ser Asn 485 490 495 500
Phe Gln Met Gin Ala Pro Pro Gly Val Gly Lys Val Asp Thr Ser Glu 505 510
Lys Gly Gly Gin Phe Ser Leu His Ile Ala Lys His Ser Thr Val Val 515 520 525 530
Phe Lys Pro Ile Ala Ala

<210> SEQ ID NO 8
<211> LENGTH: 1693
<212> TYPE: DNA
<213> ORGANISM: Nicotiana tabacum

<400> SEQUENCE: 8

cctctagct attaaaaa c tgtgccaaact ttctcaacaca accatcttttt gcaattcttt 60
ttctaatgta ttttccctat tgtgccaaatt atactctcc tacccctctaa tacctttccc 120
ttctgtagac atctcactta ttctctctct tcttcctcta atatcacaat tctctcgttt 180
taagccocaa aacaacccct caccctggtc taccagcagc ccaatttctg ttatgagctt 240
tcaaggttggg aatacatcctg agaatacacact ccttgcacca aatggtttgtc 300
tatattttta ttaaaaacttg gcctaaatag cctagctgtg gtatcgaaccc ctgagctacg 360
taaccacagtt cttcagacag caaagggcag cttggtgtgc ccgctcagcta acgtgcttt 420
tgtatatattg cagacagcag cgtgtcttctaatg gctgtcaccac aattgagctt 480
aaatgaggg cgaatattatga cgctctcatt tttatcactaa aagtggttgcc accaatatat 540
tgatatggtg gcgattagga gcatccactgt cttttgagcct tgaagaaga atgaaagat 600
gaaatagac gcgaatgtgct tttaggaaa cctccacatgt ctttgcacaa ttcacatagt 660
tgatataggg cttagctgca agttctggtc ccaagatggt ctttgcacaa aattgaggcc 720
aaagttttaat ccagacagaga gcagaggattct ccagttcttt cttcactacat atgggttat 780
tatctttcttg cgctccaatgc ctaaaataggt ctttgcacac aattgacaag aatcctcaca 840
aaggtgacct gctcttctca acaatattt ctttgaagaa gcagttgttca cctcaaatg 900
aaatgtggaa aacaaagaag ttgactatatc ttttgcacc ccttttcgca 960
agggagaaa attttttttaaattcagcctt cttgctgtgc cattagctcag 1020
tgaaactaat ctatgctgcc tggagttggc cattagcctg cttgtaaatc attcacttta 1080
ttcacagacct ttgaacgtgg aatctctaaag agctctaaaa gggaagtcag taaaaaata 1140
aaactctatt cagctggcct actctgtgac acacacaaat gaaacattaa gctccacac 1200
acccatcc ttacctgtac ccatatatc cttcagaaaa gaacagttag ttggttacta 1260
tttactcag aaaaactcaag tgggtttgtctt atcaacttctt cttgagaccc 1320
tgtggaaaaac cagcaagatt ttcgccccga ggggttctac aagggagata tgcagcaga 1380
gggcagtttt gtggtgagca agtgggtattt caggtacttt cctttctgga tggagagccc 1440
gagctgccccc ggaatattcct ttgaactgcct aatctgcttt ttggtttgact caaattgtgg 1500
tgaaatattt cagatacgct cctctctaccag tggagaaaaa gttgctcaca gttgagaaaa 1560
agggagatat cgggtcggcttc ttggagagcct tttactgtttt gtcctcaagc ttttctgtgc 1620
attactatttt actctattttaa gtttttcatt attttattatatc ttttttgtaa 1680
aaaaa aaaa aaaa 1693
Met Tyr His Leu Leu Ser Pro Ile Glu Ala Ile Val Gly Leu Val Thr
1  5  10  15
Phe Ala Phe Leu Leu Tyr Leu Leu Thr Lys Gly Ser Lys Ile
20
Leu Asn Pro Leu Pro Pro Lys Ile Pro Gly Gly Trp Pro Val Ile Gly
35  40  45
His Leu Phe Tyr Phe Asn Asn Gly Asp Asp Arg His Phe Ser
50  55  60
Gln Lys Leu Gly Asp Leu Ala Asp Tyr Gly Pro Val Phe Thr Phe
65  70  75  80
Arg Leu Gly Phe Arg Arg Phe Leu Ala Val Ser Ser Tyr Glu Ala Met
85  90  95
Lys Glu Cys Phe Ser Thr Asn Asp Ile His Phe Ala Asp Arg Pro Ala
100  105  110
Leu Leu Tyr Gly Glu Tyr Leu Cys Tyr Asn Asn Ala Met Leu Ala Val
115  120  125
Ala Lys Tyr Gly Pro Tyr Trp Lys Arg Arg Lys Leu Val Asn Glu
130  135  140
Glu Leu Leu Ser Val Ser Arg Leu Glu Lys Phe Lys His Val Arg Phe
145  150  155  160
Ser Ile Val Glu Asn Ile Lys Glu Leu Tyr Asn Cys Asp Ser Pro
165  170  175
Met Val Lys Ile Asn Leu Ser Asp Trp Ile Asp Lys Leu Thr Phe Asp
180  185  190
Ile Ile Leu Lys Met Val Val Gly Lys Thr Tyr Asn Asn Gly His Gly
195  200  205
Glu Ile Leu Lys Ala Ala Phe Gln Lys Phe Met Val Gln Ala Met Glu
210  215  220
Ile Glu Leu Tyr Asp Val Phe His Ile Pro Phe Phe Lys Trp Leu Asp
225  230  235  240
Leu Thr Gly Asn Ile Lys Ala Met Lys Gln Thr Phe Lys Asp Ile Asp
245  250  255
Asn Ile Ile Gln Gly Trp Leu Asp Glu His Ile Lys Lys Arg Glu Thr
260  265  270
Lys Asp Val Gly Gly Glu Asn Glu Asp Phe Ile Asp Val Leu Leu
275  280  285
Ser Lys Arg Ser Asn Glu His Leu Gly Asp Gly Tyr Ser His Asp Thr
290  295  300
Thr Ile Lys Ala Thr Val Phe Thr Leu Val Leu Asp Ala Thr Asp Thr
305  310  315  320
Leu Ala Leu His Ile Lys Trp Val Met Ala Leu Met Ile Asn Asn Lys
325  330  335
Asn Val Met Lys Ala Glu Glu Met Asp Thr Ile Val Gly Arg
340  345  350
Asp Arg Trp Val Glu Glu Asn Asp Ile Lys Asn Leu Val Tyr Leu Gln
355  360  365
Ala Ile Val Lys Glu Val Leu Arg Leu His Pro Pro Ala Pro Leu Ser
370  375  380
Val Gln His Leu Ser Val Lys Asp Cys Val Val Val Gln Gly Tyr His Ile
385 390 395 400
Pro Lys Gly Thr Ala Leu Leu Thr Asn Ile Met Lys Leu Gln Arg Asp
405 410 415
Pro Gln Ile Trp Val Asp Pro Asp Thr Phe Asp Pro Glu Arg Phe Leu
420 425 430
Thr Thr Thr Ala Ala Ala Ile Asp Tyr Arg Gly Gin His Tyr Glu Leu Ile
435 440 445
Pro Phe Gly Ser Gly Arg Arg Ala Cys Pro Ala Met Asn Tyr Ser Leu
450 455 460
Gln Val Glu His Leu Ser Ile Ala His Leu Ile Gln Gly Phe Asp
465 470 475 480
Ala Thr Thr Thr Asn Glu Pro Leu Asp Met Lys Gln Gln Val Gly Leu
485 490 495
Thr Leu Pro Lys Gln Thr Thr Val Glu Val Leu Ile Thr Pro Arg Leu
500 505 510
Pro Pro Thr Leu Tyr Gin Tyr
515

<210> SEQ ID NO 10
<211> LENGTH: 1578
<212> TYPE: DNA
<213> ORGANISM: Nicotiana tabacum

<400> SEQUENCE: 10

atgtaaagct tctttctcc catagaagcc attgtaggac ttgaactctt tgtatctcta
60
ccttaaagtc tatgcaaaaa aaaacatca aaaaaatcctt aagcactgcc ttcaaaatc
120
cggcagaatt cgccatctct ttattttctca acaacaatgg cagccagctac
180
cggcaagtt ttccaaacct cgggaccttc attttttc ttttggaaat ttgatgct
240
cggtaagtg cttttgggtt ctgggggttg agtagtttag aagcattgaa aagatagccc
300
tttacttgg atacttacct gcggccagcc cggcctttct cttgccagga ataccccctg
360
tttaccaca tcgctcccaaat ttttgggcttt ttttttcgact tcgggtgctatg
420
ttttatatt gcagacgttt tttttctacac gcgttcgaggt ttttttttct
480
ttttatgtgc cagagaaatt tacatatttt tactatatttt gttactttcg tttctttttc
540
ttttacatg acacacgcc atccttttttt ctcagccacc cttttttttt ccagcttttgg
600
ttttacacta atctgagctct ccagcttttt gttttttttt tttttttttt gcggggttttt
660
ttttacacta atctgagctct ccagcttttt gttttttttt tttttttttt gcggggttttt
720
ttttacacta atctgagctct ccagcttttt gttttttttt tttttttttt gcggggttttt
780
ttttacacta atctgagctct ccagcttttt gttttttttt tttttttttt gcggggttttt
840
ttttacacta atctgagctct ccagcttttt gttttttttt tttttttttt gcggggttttt
900
ttttacacta atctgagctct ccagcttttt gttttttttt tttttttttt gcggggttttt
960
ttttacacta atctgagctct ccagcttttt gttttttttt tttttttttt gcggggttttt
1020
ttttacacta atctgagctct ccagcttttt gttttttttt tttttttttt gcggggttttt
1080
ttttacacta atctgagctct ccagcttttt gttttttttt tttttttttt gcggggttttt
1140
ttttacacta atctgagctct ccagcttttt gttttttttt tttttttttt gcggggttttt
1200
ttttacacta atctgagctct ccagcttttt gttttttttt tttttttttt gcggggttttt
1260
ttttacacta atctgagctct ccagcttttt gttttttttt tttttttttt gcggggttttt
1320
ttttacacta atctgagctct ccagcttttt gttttttttt tttttttttt gcggggttttt
1380
aattactcat tgcaagggga acaacctttaa attggcctatt tgatcaggag tttcacttt 1440
Gcaaacagca cttaacgagcc ttggatatg aaccaagggg tggctcaac tttacctaag 1500
aagacagatg tggaggtctc aattacacct cgcttccccct tcagccttta tcaatattaa 1560
tacttttct tgtttgga 1578

<210> SEQ ID NO: 11
<211> LENGTH: 509
<212> TYPE: PRT
<213> ORGANISM: Nicotiana tabacum
<400> SEQUENCE: 11

Met Glu Gly Thr Asn Leu Thr Thr Tyr Ala Ala Val Phe Leu Gly Thr
1      5      10     15
Leu Phe Leu Leu Leu Leu Ser Lys Phe Leu Arg Gln Arg Lys Leu Asn
20     25     30
Leu Pro Pro Gly Pro Lys Pro Trp Pro Ile Ile Gly Aen Leu Asn Leu
35     40     45
Ile Gly Aen Leu Pro His Arg Ser Ile His Glu Leu Ser Leu Lys Tyr
50     55     60
Gly Pro Ile Met Gln Leu Gln Phe Gly Thr Phe Pro Val Val Val Gly
65     70     75     80
Ser Ser Val Glu Met Ala Lys Val Phe Leu Lys Ser Met Asp Ile Ann
95     100    105    110
Phe Val Gly Arg Pro Lys Thr Ala Ala Gly Lys Tyr Thr Thr Tyr Asn
115    120    125

Tyr Ser Asp Ile Thr Trp Ser Pro Tyr Gly Pro Tyr Trp Arg Gln Ala
130    135    140
Arg Arg Met Cys Leu Met Glu Leu Phe Ser Thr Lys Arg Leu Asp Ser
145    150    155    160
Tyr Glu Tyr Ile Arg Ala Glu Leu His Ser Leu Leu His Aen Leu
170    175    180
Asn Lys Ile Ser Gly Lys Pro Ile Val Leu Lys Asp Tyr Leu Thr Thr
190    195    200
Leu Ser Leu Ann Val Ile Ser Arg Met Val Leu Gly Arg Tyr Leu
205    210    215    220
Asp Glu Ser Glu Asn Ser Ile Val Thr Pro Glu Glu Phe Lys Lys Met

Leu Asp Glu Leu Phe Leu Leu Ann Gly Val Leu Ann Ile Gly Asp Ser
225    230    235    240
Ile Pro Trp Ile Asp Phe Met Asp Leu Gin Glu Gly Tyr Val Lys Arg Met
245    250    255
Lys Phe Val Ser Lys Lys Phe Asp Lys Phe Leu Glu His Val Ile Asp
260    265    270
Glu His Ann Val Arg Arg Glu Val Glu Asn Tyr Ile Ala Lys Asp
275    280    285
Met Val Asp Val Leu Leu Gin Leu Ala Asp Asp Pro Thr Leu Glu Val
290    295    300
Lys Leu Glu Arg His Gly Val Lys Ala Phe Thr Gin Asp Met Leu Ala
305    310    315    320
Gly Gly Thr Glu Ser Ser Ala Val Thr Val Glu Trp Ala Ile Ser Glu
325    330    335
Leu Leu Lys Lys Pro Glu Ile Phe Lys Lys Ala Thr Glu Glu Leu Asp
actattggaa gagacotac attggtggc cagcgttggg ccgtccagcc ggagaggttc 1260
cacgaaagt ccaattgtg taagaggtat gattttgagc tttgccatt tggagctggg 1320
agaagagatg gcggagggta taaccttgggg cttaaggtga tctaagcttg cttagctaat 1380
ctttatatgg gttatcagtt gtaattgcct gtaaatatga ctctgagga ctotgacatg 1440
gatagagatt tcggctcttc cacacctaaa aagtttccac ttgctactgt gattgagcca 1500
agactttccg caaaccctttg cctgtgttga 1530

<210> SEQ ID NO 13
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: derived from Nicotiana tabacum p450 gene
<400> SEQUENCE: 13
ggcgagaat ttgtcctgga atgctatttg gtttag 36

<210> SEQ ID NO 14
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: derived from Nicotiana tabacum p450 gene
<400> SEQUENCE: 14
gtacaatgt gaggttgaca atg 23

<210> SEQ ID NO 15
<211> LENGTH: 18
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: derived from Nicotiana tabacum p450 gene
<400> SEQUENCE: 15
gttggttttg atgcattg 18

<210> SEQ ID NO 16
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: derived from Nicotiana tabacum p450 gene
<400> SEQUENCE: 16
ttagcgacga atagcttgga agaca 25

<210> SEQ ID NO 17
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: derived from Nicotiana tabacum p450 gene
<400> SEQUENCE: 17
ggggatccg tggcatttctt cagctttgtt tcc 33

<210> SEQ ID NO 18
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: derived from Nicotiana tabacum p450 gene
<400> SEQUENCE: 18

 ggggaattct tactctcag aaggtgata agg 33

<210> SEQ ID NO 19
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: derived from Nicotiana tabacum p450 gene

<400> SEQUENCE: 19

cceggatcc gatcatcat ctcttttctcc 30

<210> SEQ ID NO 20
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: derived from Nicotiana tabacum p450 gene

<400> SEQUENCE: 20

 ggggaattct cactattgt aagcgtagg agg 33

<210> SEQ ID NO 21
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: derived from Nicotiana tabacum p450 gene

<400> SEQUENCE: 21

cceggatcca tgcaatccct cagctgggt tcc 33

<210> SEQ ID NO 22
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: derived from Nicotiana tabacum p450 gene

<400> SEQUENCE: 22

 ggggaagctct caatcgaag aagattgata agg 33

<210> SEQ ID NO 23
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: derived from Nicotiana tabacum p450 gene

<400> SEQUENCE: 23

gcattatcg ggcgaatct aatctccaaa ctctgggta aaaaatttca gtcoccaacct 60
gtcccaaac agtctc 75

<210> SEQ ID NO 24
<211> LENGTH: 75
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: derived from Nicotiana tabacum p450 gene

<400> SEQUENCE: 24

 gggggatgca tggatctct gctcactaga aaaaacctcg tgcgctatt gcgcgcactt 60
atcgccgca tacat 75
<210> SEQ ID NO 25
<211> LENGTH: 33
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: derived from Nicotiana tabacum p450 gene

<400> SEQUENCE: 25
sggagctct tagcagcag tagcctgaa gac 33

<210> SEQ ID NO 26
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Nicotiana tabacum p450 protein
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 7
<223> OTHER INFORMATION: Xaa = Any Amino Acid

<400> SEQUENCE: 26
Lys Glu Thr Leu Arg Leu Xaa 1 5

<210> SEQ ID NO 27
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Nicotiana tabacum p450 protein
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 4,9
<223> OTHER INFORMATION: Xaa = Any Amino Acid

<400> SEQUENCE: 27
Pro Phe Gly Xaa Gly Arg Arg Xaa Cys Pro Ala 1 5 10

<210> SEQ ID NO 28
<211> LENGTH: 11
<212> TYPE: PRT
<213> ORGANISM: Nicotiana tabacum p450 protein
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 4,8
<223> OTHER INFORMATION: Xaa = Any Amino Acid

<400> SEQUENCE: 28
Pro Phe Gly Xaa Gly Arg Arg Xaa Cys Pro Gly 1 5 10

<210> SEQ ID NO 29
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Nicotiana tabacum p450 protein
<220> FEATURE:
<221> NAME/KEY: VARIANT
<222> LOCATION: 2
<223> OTHER INFORMATION: Xaa = Any Amino Acid

<400> SEQUENCE: 29
Phe Xaa Pro Glu Arg Phe 1 5

<210> SEQ ID NO 30
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: derived from Nicotiana tabacum p450 protein
<400> SEQUENCE: 30
Ala Ala Arg Gly Ala Arg Ala Cys Ile Tyr Thr Ile Met Gly Ile Tyr
1  5  10  15
Thr Ile Cys Ala
20

<210> SEQ ID NO 31
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: derived from Nicotiana tabacum p450 protein

<400> SEQUENCE: 31
Ala Ala Arg Gly Ala Arg Ala Cys Ile Tyr Thr Ile Met Gly Ile Tyr
1  5  10  15
Thr Ile Thr Ala
20

<210> SEQ ID NO 32
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: derived from Nicotiana tabacum p450 protein

<400> SEQUENCE: 32
Ala Ala Arg Gly Ala Arg Ala Cys Ile Tyr Thr Ile Met Gly Ile Tyr
1  5  10  15
Thr Ile Met Gly
20

<210> SEQ ID NO 33
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: derived from Nicotiana tabacum p450 protein

<400> SEQUENCE: 33
Thr Thr Tyr Ile Ile Ile Cys Ile Gly Ala Arg Met Gly Ile Thr
1  5  10  15
Thr Tyr

<210> SEQ ID NO 34
<211> LENGTH: 18
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: derived from Nicotiana tabacum p450 protein

<400> SEQUENCE: 34
Arg Ala Ala Ile Cys Lys Tyr Thr Cys Ile Gly Gly Ile Ile Ile Arg
1  5  10  15
Ala Ala

<210> SEQ ID NO 35
<211> LENGTH: 20
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: derived from Nicotiana tabacum p450 protein

<400> SEQUENCE: 35
Gly Gly Ile Met Gly Ile Met Gly Ile Ile Ile Ile Thr Gly Tyr Cys
1  5  10  15
Cys Ile Gly Ser
20

SEQ ID NO: 36
LENGTH: 20
TYPE: PRT
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: derived from Nicotiana tabacum p450 protein

SEQUENCE: 36
Cys Lys Ile Cys Lys Ile Cys Cys Ile Ile Ile Cys Cys Arg Ala
1  5  10  15
Ala Ile Gly Gly
20

SEQ ID NO: 37
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: derived from T7 Bacteriophage Promoter

SEQUENCE: 37
gtaatacgac tcactatagg g
21

SEQ ID NO: 38
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: derived from T3 Bacteriophage Promoter

SEQUENCE: 38
cataatccc tcactaagg g
21

SEQ ID NO: 39
LENGTH: 500
TYPE: PRT
ORGANISM: Mentha piperita

SEQUENCE: 39
Met Glu Leu Gln Ile Ser Ser Ala Ile Ile Leu Val Val Thr Tyr
1  5  10  15
Thr Ile Ser Leu Leu Ile Ile Lys Gln Trp Arg Lys Pro Lys Pro Gln
20  25  30
Glu Asn Leu Pro Pro Gly Pro Pro Lys Leu Pro Leu Ile Gly His Leu
35  40  45
His Leu Leu Trp Gly Lys Leu Pro Gln His Ala Leu Ala Ser Val Ala
50  55  60
Lys Gln Tyr Gly Pro Val Ala His Val Gln Leu Gly Val Phe Ser
65  70  75  80
Val Val Leu Ser Ser Arg Glu Ala Thr Lys Glu Ala Met Lys Leu Val
85  90  95
Asp Pro Ala Cys Ala Asp Arg Phe Glu Ser Ile Gly Thr Lys Ile Met
100 105 110
Trp Tyr Asp Asn Asp Ile Ile Phe Ser Pro Tyr Ser Val His Trp
115 120 125
Arg Glu Met Arg Lys Ile Cys Val Ser Glu Leu Leu Ser Ala Arg Asn
130  Val Arg Ser Phe Gly Phe Ile Arg Glu Asp Arg Ser Arg Leu Leu
145  Gly His Leu Arg Ser Ser Ala Ala Gly Glu Ala Val Asp Leu Thr
160  Glu Arg Ile Ala Thr Leu Thr Cys Ser Ile Ile Cys Arg Ala Ala Phe
175  Gly Ser Val Ile Arg Asp His Glu Leu Val Glu Leu Val Lys Asp
190  Ala Leu Ser Met Ala Ser Gly Phe Glu Leu Ala Asp Met Phe Pro Ser
205  Ser Lys Leu Leu Asn Leu Leu Cys Trp Asn Lys Ser Lys Leu Thr Arg
220  Met Arg Arg Arg Val Asp Ala Ile Leu Glu Ala Ile Val Glu Glu His
235  Lys Leu Lys Lys Ser Gly Glu Phe Gly Gly Glu Asp Ile Ile Asp Val
250  Leu Phe Arg Met Glu Lys Asp Ser Glu Ile Lys Val Pro Ile Thr Thr
265  Asn Ala Ile Lys Ala Phe Ile Phe Asp Thr Phe Ser Ala Gly Thr Glu
280  Thr Ser Ser Thr Thr Thr Leu Thr Val Met Ala Glu Leu Met Arg Asn
295  Pro Glu Val Met Ala Lys Ala Asp Ala Glu Val Arg Ala Ala Leu Lys
310  Gly Lys Thr Asp Trp Asp Val Asp Val Gin Glu Leu Lys Tyr Met
325  Lys Ser Val Val Lys Glu Thr Met Arg Met His Pro Pro Ile Pro Leu
340  Ile Pro Arg Ser Cys Arg Glu Glu Cys Glu Val Asn Gly Tyr Thr Ile
355  Pro Asn Lys Ala Arg Ile Met Ile Asn Val Trp Ser Met Gly Arg Asn
370  Pro Leu Tyr Trp Glu Lys Pro Glu Thr Phe Trp Pro Glu Arg Phe Asp
385  Gln Val Ser Arg Asp Phe Met Gly Asn Phe Glu Phe Ile Pro Phe
400  Gly Ala Gly Arg Arg Ile Cys Pro Gly Leu Asn Phe Gly Leu Ala Asn
415  Val Glu Val Pro Leu Ala Gin Leu Leu Tyr His Phe Asp Trp Lys Leu
430  Ala Glu Gly Met Asn Pro Ser Asp Met Asp Met Ser Glu Ala Glu Gly
445  Leu Thr Gly Ile Arg Lys Asn Asn Leu Leu Leu Val Pro Thr Pro Tyr
460  Asp Pro Ser Ser
475
490
500

<210> SEQ ID NO 40
<211> LENGTH: 496
<212> TYPE: PRT
<213> ORGANISM: Mentha spicata
<400> SEQUENCE: 40

Met Glu Leu Asp Leu Leu Ser Ala Ile Ile Leu Val Ala Thr Tyr
<table>
<thead>
<tr>
<th>1</th>
<th>5</th>
<th>10</th>
<th>15</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ile Val Ser Leu Leu Ile Asn Gln Trp Arg Lys Ser Lys Ser Gln Gln</td>
<td>20</td>
<td>25</td>
<td>30</td>
</tr>
<tr>
<td>Asn Leu Pro Pro Ser Pro Pro Lys Leu Pro Val Ile Gly His Leu His</td>
<td>35</td>
<td>40</td>
<td>45</td>
</tr>
<tr>
<td>Phe Leu Trp Gly Leu Pro Gln His Val Phe Arg Ser Ile Ala Gln</td>
<td>50</td>
<td>55</td>
<td>60</td>
</tr>
<tr>
<td>Lys Tyr Gly Pro Val Ala His Val Gln Leu Gly Glu Val Tyr Ser Val</td>
<td>65</td>
<td>70</td>
<td>75</td>
</tr>
<tr>
<td>Val Leu Ser Ser Ala Glu Ala Ala Lys Gln Ala Met Lys Val Leu Asp</td>
<td>85</td>
<td>90</td>
<td>95</td>
</tr>
<tr>
<td>Pro Asn Phe Ala Asp Arg Phe Asp Gly Ile Gly Ser Arg Thr Met Trp</td>
<td>100</td>
<td>105</td>
<td>110</td>
</tr>
<tr>
<td>Tyr Asp Lys Asp Asp Ile Ile Phe Ser Pro Tyr Asp Asp His Trp Arg</td>
<td>115</td>
<td>120</td>
<td>125</td>
</tr>
<tr>
<td>Gln Met Arg Arg Ile Cys Val Thr Glu Leu Ser Pro Lys Asn Val</td>
<td>130</td>
<td>135</td>
<td>140</td>
</tr>
<tr>
<td>Arg Ser Phe Gly Tyr Ile Arg Gln Glu Ile Glu Arg Leu Ile Arg</td>
<td>145</td>
<td>150</td>
<td>155</td>
</tr>
<tr>
<td>Leu Leu Gly Ser Ser Gly Gly Ala Pro Val Asp Val Thr Glu Glu Val</td>
<td>165</td>
<td>170</td>
<td>175</td>
</tr>
<tr>
<td>Ser Lys Met Ser Cys Val Val Val Cys Arg Ala Ala Phe Gly Ser Val</td>
<td>180</td>
<td>185</td>
<td>190</td>
</tr>
<tr>
<td>Leu Lys Asp Glu Gly Ser Leu Ala Glu Leu Val Lys Glu Ser Leu Ala</td>
<td>195</td>
<td>200</td>
<td>205</td>
</tr>
<tr>
<td>Leu Ala Ser Gly Phe Glu Leu Ala Asp Leu Tyr Pro Ser Ser Trp Leu</td>
<td>210</td>
<td>215</td>
<td>220</td>
</tr>
<tr>
<td>Leu Asn Leu Leu Ser Leu Asn Tyr Arg Leu Gln Arg Met Arg Arg</td>
<td>225</td>
<td>230</td>
<td>235</td>
</tr>
<tr>
<td>Arg Leu Asp His Ile Leu Asp Gly Phe Leu Glu Glu His Arg Glu Lys</td>
<td>245</td>
<td>250</td>
<td>255</td>
</tr>
<tr>
<td>Lys Ser Gly Glu Phe Gly Gly Asp Ile Val Asp Val Leu Phe Arg</td>
<td>260</td>
<td>265</td>
<td>270</td>
</tr>
<tr>
<td>Met Gln Lys Gly Ser Asp Ile Lys Ile Pro Ile Thr Ser Asn Cys Ile</td>
<td>275</td>
<td>280</td>
<td>285</td>
</tr>
<tr>
<td>Lys Gly Phe Ile Phe Asp Thr Phe Ser Ala Gly Ala Glu Thr Ser Ser</td>
<td>290</td>
<td>295</td>
<td>300</td>
</tr>
<tr>
<td>Thr Thr Ile Ser Trp Ala Leu Ser Glu Leu Met Arg Asn Pro Ala Lys</td>
<td>305</td>
<td>310</td>
<td>315</td>
</tr>
<tr>
<td>Met Ala Lys Val Gln Ala Glu Val Arg Glu Ala Leu Lys Gly Lys Thr</td>
<td>325</td>
<td>330</td>
<td>335</td>
</tr>
<tr>
<td>Val Val Asp Leu Ser Glu Val Gln Glu Leu Lys Tyr Leu Arg Ser Val</td>
<td>340</td>
<td>345</td>
<td>350</td>
</tr>
<tr>
<td>Leu Lys Glu Thr Leu Arg Leu His Pro Pro Phe Pro Leu Ile Pro Arg</td>
<td>355</td>
<td>360</td>
<td>365</td>
</tr>
<tr>
<td>Gln Ser Arg Glu Glu Cys Glu Val Asp Gly Tyr Thr Ile Pro Ala Lys</td>
<td>370</td>
<td>375</td>
<td>380</td>
</tr>
<tr>
<td>Thr Arg Ile Phe Ile Asn Val Trp Ala Ile Gly Arg Asp Pro Gln Tyr</td>
<td>385</td>
<td>390</td>
<td>395</td>
</tr>
<tr>
<td>Trp Glu Asp Pro Asp Thr Phe Arg Pro Glu Arg Phe Asp Glu Val Ser</td>
<td>405</td>
<td>410</td>
<td>415</td>
</tr>
<tr>
<td>Arg Asp Phe Met Gly Asn Asp Phe Glu Phe Ile Pro Phe Gly Ala Gly</td>
<td>420</td>
<td>425</td>
<td>430</td>
</tr>
</tbody>
</table>
Arg Arg Ile Cys Pro Gly Leu His Phe Gly Leu Ala Asn Val Glu Ile 435 440
Pro Leu Ala Gin Leu Leu Tyr His Phe Asp Trp Lys Leu Pro Gin Gly 450 455 460
Met Thr Asp Ala Asp Leu Asp Met Thr Glu Thr Pro Gly Leu Ser Gly 465 470 475 480
Pro Lys Lys Lys Asn Val Cys Leu Val Pro Thr Leu Tyr Lys Ser Pro 485 490 495

<210> SEQ ID NO 41
<211> LENGTH: 509
<212> TYPE: PRT
<213> ORGANISM: Nepeta racemosa

<400> SEQUENCE: 41

Met Val Ser Leu Ser Tyr Phe Leu Ile Ala Leu Leu Cys Thr Leu Pro 1 5 10 15
Phe Leu Leu Phe Leu Asn Lys Trp Arg Arg Ser Tyr Ser Gly Lys Thr 20 25 30
Pro Pro Pro Ser Pro Pro Lys Leu Pro Val Ile Gly Asn Leu His Gln 35 40 45
Leu Gly Leu Tyr Pro His Arg Tyr Leu Gin Ser Leu Ser Arg Arg Tyr 50 55 60
Gly Pro Leu Met Gin Leu His Phe Gly Ser Val Pro Val Leu Val Ala 65 70 75 80
Ser Ser Pro Gin Ala Ala Arg Glu Ile Met Lys Asn Gln Asp Ile Val 85 90 95
Phe Ser Asn Arg Pro Lys Met Ser Ile Ala Asn Arg Leu Phe Phe Asn 100 105 110
Asn Arg Asp Val Ala Phe Thr Gin Tyr Gly Tyr Trp Arg Gin Ile 115 120 125
Arg Ser Ile Cys Val Leu Gin Leu Leu Ser Asn Lys Arg Val Gin Ser 130 135 140
Phe Arg Arg Val Arg Glu Glu Thr Ser Ile Met Val Glu Lys Ile 145 150 155 160
Met Gin Leu Gly Ser Ser Ser Ser Thr Pro Val Asn Leu Ser Glu Leu 165 170 175
Leu Leu Ser Leu Thr Asn Asp Val Val Cys Arg Val Thr Leu Gly Lys 180 185 190
Lys Tyr Gly Gly Gly Asn Gly Ser Glu Val Gin Asp Leu Lys Glu 195 200 205
Met Leu Thr Glu Ile Gin Asn Leu Met Gly Ile Ser Pro Val Trp Glu 210 215 220
Phe Ile Pro Trp Leu Asn Trp Thr Arg Arg Phe Asp Gly Val Asp Gin 225 230 235 240
Arg Val Asp Arg Ile Val lys Ala Phe Asp Gly Phe Leu Glu Ser Val 245 250 255
Ile Gin Glu His Lys Glu Arg Asp Gly Lys Asp Gly Asp Gly Asp 260 265 270
Gly Ala Leu Asp Phe Val Asp Ile Leu Leu Gin Phe Gin Arg Glu Asn 275 280 285
Lys Asn Arg Ser Pro Val Gin Asp Gin Thr Val Lys Ala Leu Ile Leu 290 295 300
Asp Met Phe Val Ala Gly Thr Asp Thr Thr Ala Thr Ala Leu Glu Trp 305 310 315 320
Ala Val Ala Glu Leu Ile Lys Asn Pro Arg Ala Met Lys Arg Leu Gln 325 330 335
Asn Glu Val Arg Glu Val Ala Gly Ser Lys Ala Glu Glu Glu Glu 340 345 350
Asp Leu Glu Lys Met Pro Tyr Leu Ala Ser Lys Ala Ile Lys Glu Ser Leu 355 360 365
Arg Leu His Val Pro Val Val Leu Val Pro Arg Glu Ser Thr Arg 370 375 380
Asp Thr Asn Val Leu Gly Tyr Asp Ile Ala Ser Gly Thr Arg Val Leu 385 390 395 400
Ile Asn Ala Trp Ala Ile Ala Arg Asp Pro Ser Val Trp Glu Asn Pro 405 410 415
Glu Glu Phe Leu Pro Glu Arg Phe Leu Asp Ser Ser Ile Asp Tyr Lys 420 425 430
Gly Leu His Phe Glu Leu Pro Gly Gly Ala Gly Arg Arg Gly Cys 435 440 445
Pro Gly Ala Thr Phe Ala Val Ala Ile Asp Glu Leu Ala Ala Leu Lys 450 455 460
Leu Val His Lys Phe Asp Phe Gly Leu Pro Asn Gly Ala Arg Met Glu 465 470 475 480
Glu Leu Asp Met Ser Glu Thr Ser Gly Met Thr Val His Lys Lys Ser 485 490 495
Pro Leu Leu Leu Leu Pro Ile Pro His His Ala Ala Pro 500 505

<210> SEQ ID NO 42
<211> LENGTH: 471
<212> TYPE: PRT
<213> ORGANISM: Persea americana

<400> SEQUENCE: 42
Met Ala Ile Leu Val Ser Leu Leu Phe Leu Ala Ile Ala Leu Thr Phe 1 5 10 15
Phe Leu Leu Lys Leu Asn Glu Lys Arg Glu Lys Pro Asn Leu Pro 20 25 30
Pro Ser Pro Pro Asn Leu Pro Ile Ile Gly Asn Leu His Gln Leu Gly 40 45
Asn Leu Pro His Arg Ser Leu Arg Ser Leu Ala Asn Glu Leu Gly Pro 50 55 60
Leu Ile Leu Leu His Leu Gly His Ile Pro Thr Leu Ile Val Ser Thr 65 70 75 80
Ala Glu Ile Ala Glu Ile Leu Lys Thr His Arg Leu Ile Phe Ala 85 90 95
Ser Arg Pro Ser Thr Thr Ala Ala Arg Arg Ile Phe Tyr Asp Cys Thr 100 105 110
Asp Val Ala Phe Ser Pro Tyr Gly Glu Tyr Trp Arg Gln Val Arg Lys 115 120 125
Ile Cys Val Leu Glu Leu Leu Ser Ile Lys Arg Val Asn Ser Tyr Arg 130 135 140
Ser Ile Arg Glu Glu Val Gly Leu Met Met Glu Arg Ile Ser Gln 145 150 155 160
Ser Cys Ser Thr Gly Glu Ala Val Asn Leu Ser Glu Leu Leu Leu 165 170 175
Leu Ser Ser Gly Thr Ile Thr Arg Val Ala Phe Gly Lys Tyr Glu 180 185 190
<table>
<thead>
<tr>
<th>Gly</th>
<th>Glu</th>
<th>Glu</th>
<th>Arg</th>
<th>Lys</th>
<th>Arg</th>
<th>Lys</th>
<th>Phe</th>
<th>Ala</th>
<th>Asp</th>
<th>Leu</th>
<th>Ala</th>
<th>Thr</th>
<th>Glu</th>
<th>Leu</th>
</tr>
</thead>
<tbody>
<tr>
<td>195</td>
<td>200</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thr</td>
<td>Thr</td>
<td>Leu</td>
<td>Met</td>
<td>Gly</td>
<td>Ala</td>
<td>Phe</td>
<td>Phe</td>
<td>Val</td>
<td>Gly</td>
<td>Asp</td>
<td>Tyr</td>
<td>Phe</td>
<td>Pro</td>
<td>Ser</td>
</tr>
<tr>
<td>210</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ala</td>
<td>Trp</td>
<td>Val</td>
<td>Asp</td>
<td>Val</td>
<td>Leu</td>
<td>Thr</td>
<td>Gly</td>
<td>Met</td>
<td>Asp</td>
<td>Ala</td>
<td>Arg</td>
<td>Leu</td>
<td>Arg</td>
<td>Asn</td>
</tr>
<tr>
<td>225</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>235</td>
</tr>
<tr>
<td>His</td>
<td>Gly</td>
<td>Glu</td>
<td>Leu</td>
<td>Asp</td>
<td>Ala</td>
<td>Phe</td>
<td>Val</td>
<td>Asp</td>
<td>His</td>
<td>Val</td>
<td>Ile</td>
<td>Asp</td>
<td>Arg</td>
<td>His</td>
</tr>
<tr>
<td>245</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>250</td>
</tr>
<tr>
<td>Leu</td>
<td>Ser</td>
<td>Arg</td>
<td>Lys</td>
<td>Ala</td>
<td>Asn</td>
<td>Gly</td>
<td>Ser</td>
<td>Asp</td>
<td>Gly</td>
<td>Val</td>
<td>Glu</td>
<td>Gln</td>
<td>Lys</td>
<td>Asp</td>
</tr>
<tr>
<td>260</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>265</td>
</tr>
<tr>
<td>Val</td>
<td>Asp</td>
<td>Val</td>
<td>Leu</td>
<td>Leu</td>
<td>His</td>
<td>Leu</td>
<td>Gln</td>
<td>Lys</td>
<td>Ser</td>
<td>Ser</td>
<td>Leu</td>
<td>Gly</td>
<td>Val</td>
<td>His</td>
</tr>
<tr>
<td>275</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>280</td>
</tr>
<tr>
<td>Leu</td>
<td>Asn</td>
<td>Arg</td>
<td>Asn</td>
<td>Leu</td>
<td>Lys</td>
<td>Val</td>
<td>Ile</td>
<td>Leu</td>
<td>Asp</td>
<td>Met</td>
<td>Phe</td>
<td>Ser</td>
<td>Gly</td>
<td></td>
</tr>
<tr>
<td>290</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>295</td>
</tr>
<tr>
<td>Gly</td>
<td>Thr</td>
<td>Asp</td>
<td>Thr</td>
<td>Thr</td>
<td>Ala</td>
<td>Val</td>
<td>Thr</td>
<td>Leu</td>
<td>Glu</td>
<td>Trp</td>
<td>Ala</td>
<td>Met</td>
<td>Ala</td>
<td>Glu</td>
</tr>
<tr>
<td>305</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>310</td>
</tr>
<tr>
<td>Ile</td>
<td>Lys</td>
<td>His</td>
<td>Pro</td>
<td>Asp</td>
<td>Val</td>
<td>Met</td>
<td>Glu</td>
<td>Lys</td>
<td>Ala</td>
<td>Glu</td>
<td>Gln</td>
<td>Gln</td>
<td>Glu</td>
<td>Val</td>
</tr>
<tr>
<td>325</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>330</td>
</tr>
<tr>
<td>Val</td>
<td>Val</td>
<td>Gly</td>
<td>Lys</td>
<td>Ala</td>
<td>Lys</td>
<td>Val</td>
<td>Glu</td>
<td>Glu</td>
<td>Asp</td>
<td>Leu</td>
<td>His</td>
<td>Gln</td>
<td>Leu</td>
<td></td>
</tr>
<tr>
<td>340</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>345</td>
</tr>
<tr>
<td>His</td>
<td>Tyr</td>
<td>Leu</td>
<td>Lys</td>
<td>Leu</td>
<td>Ile</td>
<td>Ile</td>
<td>Lys</td>
<td>Glu</td>
<td>Thr</td>
<td>Leu</td>
<td>Arg</td>
<td>Leu</td>
<td>His</td>
<td>Pro</td>
</tr>
<tr>
<td>355</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>360</td>
</tr>
<tr>
<td>Ala</td>
<td>Pro</td>
<td>Leu</td>
<td>Leu</td>
<td>Val</td>
<td>Pro</td>
<td>Arg</td>
<td>Glu</td>
<td>Ser</td>
<td>Thr</td>
<td>Arg</td>
<td>Asp</td>
<td>Val</td>
<td>Val</td>
<td>Ile</td>
</tr>
<tr>
<td>370</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>375</td>
</tr>
<tr>
<td>Gly</td>
<td>Tyr</td>
<td>His</td>
<td>Ile</td>
<td>Pro</td>
<td>Ala</td>
<td>Lys</td>
<td>Thr</td>
<td>Arg</td>
<td>Val</td>
<td>Phe</td>
<td>Ile</td>
<td>Asn</td>
<td>Ala</td>
<td>Trp</td>
</tr>
<tr>
<td>385</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>390</td>
</tr>
<tr>
<td>Ile</td>
<td>Gly</td>
<td>Arg</td>
<td>Asp</td>
<td>Pro</td>
<td>Lys</td>
<td>Ser</td>
<td>Trp</td>
<td>Glu</td>
<td>Asn</td>
<td>Ala</td>
<td>Glu</td>
<td>Phe</td>
<td>Leu</td>
<td>Pro</td>
</tr>
<tr>
<td>405</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>410</td>
</tr>
<tr>
<td>Glu</td>
<td>Arg</td>
<td>Phe</td>
<td>Val</td>
<td>Asn</td>
<td>Ser</td>
<td>Val</td>
<td>Asp</td>
<td>Phe</td>
<td>Lys</td>
<td>Gly</td>
<td>Gln</td>
<td>Asp</td>
<td>Phe</td>
<td>Gln</td>
</tr>
<tr>
<td>420</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>425</td>
</tr>
<tr>
<td>Leu</td>
<td>Ile</td>
<td>Pro</td>
<td>Phe</td>
<td>Gly</td>
<td>Ala</td>
<td>Gly</td>
<td>Arg</td>
<td>Arg</td>
<td>Gly</td>
<td>Cys</td>
<td>Pro</td>
<td>Gly</td>
<td>Ile</td>
<td>Ala</td>
</tr>
<tr>
<td>435</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>440</td>
</tr>
<tr>
<td>Gly</td>
<td>Ile</td>
<td>Ser</td>
<td>Ser</td>
<td>Val</td>
<td>Glu</td>
<td>Ile</td>
<td>Ser</td>
<td>Leu</td>
<td>Ala</td>
<td>Asn</td>
<td>Leu</td>
<td>Leu</td>
<td>Tyr</td>
<td>Trp</td>
</tr>
<tr>
<td>450</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>455</td>
</tr>
<tr>
<td>Asn</td>
<td>Trp</td>
<td>Glu</td>
<td>Leu</td>
<td>Pro</td>
<td>Gly</td>
<td>Ile</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>465</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>470</td>
</tr>
</tbody>
</table>

<210> SEQ ID NO 43
<211> LENGTH: 509
<212> TYPE: PRT
<213> ORGANISM: Arabidopsis thaliana

<400> SEQUENCE: 43

Met Ala Phe Phe Ser Met Ile Ser Ile Leu Leu Gly Phe Val Ile Ser
1   5   10  15
Ser Phe Ile Phe Phe Phe Phe Lys Leu Leu Ser Phe Ser Arg
 20  25  30
Lys Asn Met Ser Glu Val Ser Thr Leu Pro Ser Val Pro Val Val Pro
 35  40  45
Gly Phe Pro Val Ile Gly Asn Leu Leu Glu Val Lys Glu Lys Pro
 50  55  60
His Lys Thr Phe Thr Arg Trp Ser Glu Ile Tyr Gly Pro Ile Tyr Ser
 65  70  75  80
Ile Lys Met Gly Ser Ser Ser Leu Ile Val Leu Asn Ser Thr Glu Thr
 85  90  95
<table>
<thead>
<tr>
<th>Sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ala Lys Glu Ala Met Val Thr Arg Phe Ser Ser Ile Ser Thr Arg Lys</td>
</tr>
</tbody>
</table>
| 100 | 105 | 110  
| Leu Ser Asn Ala Leu Thr Val Leu Thr Cys Asp Lys Ser Met Val Ala |  
| 115 | 120 | 125  
| Thr Ser Asp Tyr Asp Phe His Lys Leu Val Lys Arg Cys Leu Leu |  
| 130 | 135 | 140  
| Asn Gly Leu Leu Gly Ala Asn Ala Gln Lys Arg Lys Arg His Tyr Arg |  
| 145 | 150 | 155 | 160  
| Asp Ala Leu Ile Glu Asn Val Ser Ser Lys Leu His Ala His Ala Arg |  
| 165 | 170 | 175  
| Asp His Pro Gln Glu Pro Val Asn Phe Arg Ala Ile Phe Glu His Glu |  
| 180 | 185 | 190  
| Leu Phe Gly Val Ala Leu Lys Gln Ala Phe Gly Lys Asp Val Glu Ser |  
| 195 | 200 | 205  
| Ile Tyr Val Lys Glu Leu Gly Val Thr Leu Ser Lys Asp Glu Ile Phe |  
| 210 | 215 | 220  
| Lys Val Leu Val His Asp Met Met Glu Gly Ala Ile Asp Val Asp Trp |  
| 225 | 230 | 235 | 240  
| Arg Asp Phe Phe Pro Tyr Leu Lys Trp Ile Pro Asn Lys Ser Phe Glu |  
| 245 | 250 | 255  
| Ala Arg Ile Gln Gln Lys His Lys Arg Arg Leu Ala Val Met Asn Ala |  
| 260 | 265 | 270  
| Leu Ile Gln Asp Arg Leu Lys Gln Asn Gly Ser Glu Ser Asp Asp Asp |  
| 275 | 280 | 285  
| Cys Tyr Leu Asn Phe Leu Met Ser Glu Ala Lys Thr Leu Thr Lys Glu |  
| 290 | 295 | 300  
| Gln Ile Ala Ile Leu Val Trp Glu Thr Ile Ile Glu Thr Ala Asp Thr |  
| 305 | 310 | 315 | 320  
| Thr Leu Val Thr Thr Glu Trp Ala Ile Tyr Glu Leu Ala Lys His Pro |  
| 325 | 330 | 335  
| Ser Val Gln Asp Arg Leu Cys Lys Glu Ile Gln Asn Val Cys Gly Gly |  
| 340 | 345 | 350  
| Glu Lys Phe Lys Glu Glu Leu Ser Gln Val Pro Tyr Leu Asn Gly |  
| 355 | 360 | 365  
| Val Phe His Glu Thr Leu Arg Lys Tyr Ser Pro Ala Pro Leu Val Pro |  
| 370 | 375 | 380  
| Ile Arg Tyr Ala His Glu Asp Thr Gln Ile Gly Gly Tyr His Val Pro |  
| 385 | 390 | 395 | 400  
| Ala Gly Ser Glu Ile Ala Ile Asn Ile Tyr Gly Cys Asn Met Asp Lys |  
| 405 | 410 | 415  
| Lys Arg Trp Glu Arg Pro Glu Asp Trp Trp Pro Glu Arg Phe Leu Asp |  
| 420 | 425 | 430  
| Asp Gly Lys Tyr Glu Thr Ser Asp Leu His Lys Thr Met Ala Phe Gly |  
| 435 | 440 | 445  
| Ala Gly Lys Arg Val Cys Ala Gly Ala Leu Gln Ala Ser Leu Met Ala |  
| 450 | 455 | 460  
| Gly Ile Ala Ile Gly Arg Leu Val Gln Glu Phe Glu Trp Lys Leu Arg |  
| 465 | 470 | 475 | 480  
| Asp Gly Glu Glu Glu Asn Val Asp Thr Tyr Gly Leu Thr Ser Glu Lys |  
| 485 | 490 | 495  
| Leu Tyr Pro Leu Met Ala Ile Ile Asn Pro Arg Arg Ser |  
| 500 | 505 |
We claim:

1. A method for producing an isoprenoid compound, comprising:
   a) culturing a host cell under conditions suitable for expressing a first recombinant protein comprising an isoprenoid synthase and a second recombinant protein comprising a CYP71, CYP73, CYP82, or a CYP92 family cytochrome P450 polypeptide and under conditions for producing an isoprenoid compound, wherein:
      a) CYP71, CYP73, CYP82, and CYP92 family cytochrome P450 polypeptide is encoded by nucleic acid that can be amplified with degenerate primers based on one of SEQ ID Nos. 26-29;
      the CYP71, CYP73, CYP82, and CYP92 family cytochrome P450 polypeptide has hydroxylase activity; and
     the first and second recombinant protein together catalyze the formation of an isoprenoid compound not normally produced by said host cell, wherein the cytochrome P450 polypeptide is selected among polypeptides comprising at least 80% identity to polypeptides having an amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 and SEQ ID NO: 11; and
   b) recovering the isoprenoid compound.

2. The method of claim 1, wherein said cytochrome P450 polypeptide is selected from the group consisting of a polypeptide comprising at least 80% identity to the amino acid sequence of SEQ ID NO: 5, and a polypeptide comprising at least 80% identity to the amino acid sequence of SEQ ID NO: 7.

3. A method of claim 1, wherein said cytochrome P450 polypeptide is selected from the group consisting of a polypeptide comprising at least 80% identity to the amino acid sequence of SEQ ID NO: 9, and a polypeptide comprising at least 80% identity to the amino acid sequence of SEQ ID NO: 11.

4. A method for producing an altered isoprenoid compound, comprising:
   contacting an isoprenoid compound with an isolated CYP71, CYP73, CYP82, or a CYP92 family cytochrome P450 polypeptide, wherein:
      a) CYP71, CYP73, CYP82, and CYP92 family cytochrome P450 polypeptide is encoded by nucleic acid that can be amplified with degenerate primers based on one of SEQ ID Nos. 26-29;
      the P450 polypeptide catalyzes the formation of an isoprenoid compound, under conditions allowing for the dual hydroxylation, oxidation, demethylation, methylation, or any combination thereof of said compound to produce an altered isoprenoid compound; and
   recovering said altered isoprenoid compound, wherein the isolated P450 polypeptide comprises an amino acid sequence at least 80% identical to the amino acid sequence set forth in one of SEQ ID NOs: 1, 3, 5, 7, 9 and 11.

5. The method of claim 4, wherein the isolated P450 polypeptide comprises an amino acid sequence at least 80% identical to the amino acid sequence of SEQ ID NO: 5 or of SEQ ID NO: 7.

6. The method of claim 4, wherein the isolated P450 polypeptide comprises an amino acid sequence at least 80% identical to the amino acid sequence of SEQ ID NO: 9 or of SEQ ID NO: 11.

7. The method of claim 4, wherein the isolated P450 polypeptide comprises an amino acid sequence that is encoded by a nucleic acid sequence at least 80% identical to the nucleic acid sequence of SEQ ID NO: 2 or of SEQ ID NO: 4.

8. The method of claim 4, wherein the isolated P450 polypeptide comprises an amino acid sequence that is encoded by a nucleic acid sequence at least 80% identical to the nucleic acid sequence of SEQ ID NO: 6 or of SEQ ID NO: 8.

9. The method of claim 4, wherein the isolated P450 polypeptide comprises an amino acid sequence that is encoded by a nucleic acid sequence at least 80% identical to the nucleic acid sequence of SEQ ID NO: 10 or of SEQ ID NO: 12.

10. A host cell expressing a first recombinant protein comprising an isoprenoid synthase and a second recombinant protein comprising a CYP71, CYP73, CYP82, or a CYP92 family cytochrome P450 polypeptide, wherein:
     the second recombinant protein has hydroxylase activity;
     the first and second recombinant protein together catalyze the formation of an isoprenoid compound not normally produced by said host cell;
     the first and second recombinant proteins are heterologous to the host cell; and
     the cytochrome P450 polypeptide comprises an amino acid sequence at least 80% identical to the amino acid sequence set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 or SEQ ID NO: 11.

11. The host cell of claim 10, wherein the cytochrome P450 polypeptide comprises an amino acid sequence at least 80% identical to the amino acid sequence of SEQ ID NO: 5 or of SEQ ID NO: 7.

12. The host cell of claim 10, wherein the P450 polypeptide comprises an amino acid sequence at least 80% identical to the amino acid sequence of SEQ ID NO: 9 or of SEQ ID NO: 11.

13. The host cell of claim 10, wherein the P450 polypeptide comprises an amino acid sequence that is encoded by a nucleic acid sequence at least 80% identical to the nucleic acid sequence of SEQ ID NO: 2 or of SEQ ID NO: 4.

14. The host cell of claim 10, wherein the P450 polypeptide comprises an amino acid sequence that is encoded by a nucleic acid sequence at least 80% identical to the nucleic acid sequence of SEQ ID NO: 6 or of SEQ ID NO: 8.

15. The host cell of claim 10, wherein the P450 polypeptide comprises an amino acid sequence that is encoded by a nucleic acid sequence at least 80% identical to the nucleic acid sequence of SEQ ID NO: 10 or of SEQ ID NO: 12.

16. The host cell of claim 10 that is a yeast cell, a bacterial cell, insect cell or plant cell.

17. The method of claim 1, wherein the cytochrome P450 polypeptide has at least 80% identity to a polypeptide having the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 3.

18. The host cell of claim 10, wherein the cytochrome P450 polypeptide has at least 80% identity to a polypeptide having the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 3.

19. The method of claim 4, wherein the cytochrome P450 polypeptide has at least 80% identity to a polypeptide having the amino acid sequence set forth in SEQ ID NO: 1 or SEQ ID NO: 3.

20. The method of claim 4, wherein the P450 polypeptide catalyzes an oxidation reaction to produce an altered isoprenoid compound.
It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the Title Page:

The first or sole Notice should read --

Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 60 days.

Signed and Sealed this
Fifteenth Day of January, 2013

David J. Kappos
Director of the United States Patent and Trademark Office
IN THE SPECIFICATION:

At column 1, line 37, please replace "(BAS)" with -(EAS)-;

at column 1, line 41, please replace "BAS" with -EAS-;

at column 1, line 44, please replace "Biochemical" with -biochemical-;

at column 3, line 58, please replace "80 or 85%" with -80 or 85%-

at column 14, lines 6-8, please replace 

"5'-GCCATTATCGGCACAATACTAATCT
CCAAAATTCGGGTAAATAATCAAGCTCCCACCTGGTCACACGACAGTC-3'

with 

"5'-GCCATTATCGGCACAATACTAATCTCCAAAATTCGGGTAAATAATCAAGCTCCCACCTGGTCACACGACAGTC-3'

and

at column 14, lines 9-12, please replace 

"5'-GGGGGATCCATGGACCTCTCTC
ATAGAAAAACAACCTCGCCCTATTTCGGCCCAATTTCGGCCGCAATACTA-3'

with 

"5'-GGGGGATCCATGGACCTCTCTC
ATAGAAAAACAACCTCGCCCTATTTCGGCCCAATTTCGGCCGCAATACTA-3'

Signed and Sealed this
Seventeenth Day of September, 2013

Teresa Stanek Rea
Deputy Director of the United States Patent and Trademark Office